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Abstract

The World Health Organization (WHO) has identified hypertension (HTN) as a
global epidemic, and in accordance, has emphasized the need for cost effective,
widely available alternative methods to lower blood pressure (BP) levels in all
populations worldwide. Exercise, namely aerobic with dynamic resistance
exercise as an adjunct, is a cornerstone method of reducing HTN. Recently,
isometric handgrip (IHG) training, has become a formal recommendation of the
American College of Cardiology (ACC), and the American Heart Association
(AHA) in their recent guidelines. However, traditional IHG requires the use of a
computerized dynamometer, which costs upwards of approximately $600 CAD,
making the investigation of more cost-effective devices with a high probability for
uptake warranted. However, prior to establishing the BP-lowering effectiveness
of these devices, the acute stimuli need to be quantified. Therefore, the purpose
of this thesis was to compare the heart rate (HR), BP, and rates of perceived
exertion (RPE) to a bout of IHG performed using traditional computerized device
and a more affordable inflatable stress ball (approximately $4 CAD) among 20
healthy adults with normal BP (average age of 24.70 ± 5.13 years; average
resting BP 107.93 ± 16.14/58.68 ± 6.77; average HR 66.01 ± 8.61; 10 women).
No statistically significant differences between these two devices were observed
with respect to HR, BP, and RPE (all p > 0.05). The similar cardiovascular and
psychophysical responses between devices provide support for the potential use
of the inflatable stress ball as an effective IHG device, and thus, lay the
foundation for a future training study.

iv

Acknowledgments

This thesis is dedicated to everyone who has been a part of my journey through
the process, who offered words of encouragement, motivation, and perspective.
Thank you.
I would like to thank my advisors Dr. Cheri McGowan and Dr. Paula van Wyk for
giving me the opportunity to be a part of academia at this level, for their belief in
me as a student, for guidance, expertise, and patience with me over the course
of my graduate experience. Words alone do not fully express my gratitude.
I would also like to thank my committee members Dr. Ian Swaine for providing
multiple ideas on how to complete this project and Dr. Jamie Crawley for being
incredibly supportive through this process as well. Both of your expertise,
guidance, and patience is greatly appreciated.

To my family, friends, and lab mates, thank you for the support and motivation
throughout both my undergraduate and graduate degree, it is invaluable and I will
always remember.
Finally, I would like to thank a specific loved one for sticking by me when things
got hard, always encouraging me, and being there when I needed you. We have
both had many trials and tests during this process, and your perseverance and
attitude were inspiring. Thank you.

v

Table of Contents
Declaration of Originality................................................................................... iii
Abstract .............................................................................................................. iv
Acknowledgments .............................................................................................. v
List of Tables .................................................................................................... viii
List of Figures .................................................................................................... ix
List of Appendices...............................................................................................x
Abbreviations ..................................................................................................... xi

Chapter 1: Literature Review.............................................................................. 1
1.1 Cardiovascular Disease................................................................................ 2
1.2 Hypertension ................................................................................................. 3
1.2.1 Blood Pressure Measurement................................................................... 7
Auscultatory Sphygmomanometry ............................................................ 7
Oscillometry ................................................................................................. 8
Ambulatory Blood Pressure...................................................................... 11
1.2.2 Blood Pressure Regulation ..................................................................... 12
Neural Blood Pressure Regulation ........................................................... 13
Hormonal Control of Blood Pressure ....................................................... 17
Local Control of Blood Pressure .............................................................. 23
1.2.3 Pathophysiology of Hypertension .......................................................... 25
1.2.4 Treatment of Hypertension...................................................................... 36
1.2.5 Exercise Training ..................................................................................... 39
Effects of Acute Aerobic Exercise on Blood Pressure ........................... 39
Effects of Chronic Aerobic Exercise on Blood Pressure ....................... 40
Effects of Acute Dynamic Resistance Exercise on Blood Pressure ..... 42
Effects of Chronic Dynamic Resistance Exercise on Blood Pressure .. 44

vi

1.3 Isometric Resistance Exercise................................................................... 45
Effects of Acute Isometric Handgrip on Blood Pressure ....................... 46
Effects of Chronic Isometric Handgrip on Blood Pressure .................... 48
1.4 Alternative Devices: Stress Ball ................................................................ 50
1.5 Summary ...................................................................................................... 52
References ..................................................................................................... 54

Chapter 2: .......................................................................................................... 84
2.1 Introduction................................................................................................. 85
2.2 Purposes and Hypotheses ......................................................................... 88
2.3 Clinical Significance....................................................................................88
2.4 Methods ....................................................................................................... 89
2.4.1 Study Participants............................................................................. 89
2.4.2 Study Design ..................................................................................... 89
2.4.3 Statistical Analysis .................................................................................. 92
2.5 Results ......................................................................................................... 93
2.5.1 Comparison of Blood Pressure and Heart Rate .................................... 93
2.5.2 Comparison of Subjective Rating of Perceived Exertion ..................... 95
2.6 Discussion ................................................................................................... 96
2.7 Research Impact and Future Directions.................................................... 98
References ................................................................................................... 100
Appendices.......................................................................................................106
Vita Auctoris.....................................................................................................140

vii

List of Tables
Table 1: Participant Characteristics................................................................93
Table 2: Cardiovascular Effects.......................................................................95
Table 3: Subjective Rating of Perceived Exertion..........................................96

viii

List of Figures
Figure 1: Testing Protocol................................................................................92

ix

List of Appendices
Appendix A: Recruitment Poster, Email Script, Presentation Script.......... 106
Appendix B: Letter of Consent and Letter of Information........................... 108
Appendix C: Computerized IHG Device......................................................... 118
Appendix D: Inflatable Stress Ball................................................................. 119
Appendix E: Physical Activity Readiness Questionnaire Plus (PAR-Q +) 120
Appendix F: Intake Medical Questionnaire.................................................. 124
Appendix G: Automated Oscillometry Device / DINAMAP…………………. 125
Appendix H: Digital Air Pressure Gauge....................................................... 126
Appendix I: Borg CR-10 Scale (RPE)............................................................. 127
Appendix J: Systolic Blood Pressure Results.............................................. 128
Appendix K: Diastolic Blood Pressure Results............................................ 131
Appendix L: Heart Rate Results..................................................................... 134
Appendix M: Rating of Perceived Exertion Results..................................... 137

x

Abbreviations
Ach
ACSM
AHA
ANP
AOBP
ATP
AV
Ca2+
cAMP
CC
CCC
CVD
DASH
DBP
E
eNOS
EPR
ET-1
IHG
IL
HR
HTN
K+
MAP
mmHg
MSNA
NA+/K+
NE
NO
NOS
nNOS
OBPM
PACR
PAO2
PCAO2
PEH
PICC
PKA
PNS
Q
RAAS
SA
SBP
SNS

Acetylcholine
American College of Sports Medicine
American Heart Association
Atrial Natriuretic Peptide
Automated Office Blood Pressure Measurement
Adenosine Triphosphate
Arginine Vasopressin
Calcium
Cyclic Adenosine Monophosphate
Central Command Center
Cardiovascular Control Center
Cardiovascular Disease
Dietary Approach to Stop Hypertension
Diastolic Blood Pressure
Epinephrine
Endothelial Nitric Oxide Synthase
Exercise Pressor Reflex
Endothelin-1
Isometric Handgrip
Isometric Leg
Heart Rate
Hypertension
Potassium
Mean Arterial Blood Pressure
Millimeters of Mercury
Muscle Sympathetic Nerve Activity
Sodium/Potassium
Norepinephrine
Nitric Oxide
Nitric Oxide Synthase
Neuronal Nitric Oxide Synthase
Office Blood Pressure Measurement
Physical Activity and Cardiovascular Research
Partial Pressure of Oxygen
Partial Pressure of Carbon Dioxide
Post-Exercise Hypotension
Peripherally Inserted Central Catheter
Protein Kinase A
Parasympathetic Nervous System
Cardiac Output
Renin Angiotensin Aldosterone System
Sinoatrial
Systolic Blood Pressure
Sympathetic Nervous System

xi

SV
TPR
WHO

Stroke Volume
Total Peripheral Resistance
World Health Organization

xii

Chapter 1: Literature Review

1.1 Cardiovascular Disease
Cardiovascular disease (CVD) is the number one cause of death globally
(WHO, 2017). CVD is a classification of disorders that affects the heart and blood
vessels, and includes coronary heart (artery) disease, cerebrovascular disease,
peripheral arterial disease, congenital heart disease, and acute events such as a
myocardial infraction (heart attack) or stroke (WHO, 2017). In 2015, over 17
million or 31% of all global deaths were attributed to CVD (WHO, 2017). CVD
currently affects approximately 6% of Canadians (7% of men and 5% of women)
(Statistics Canada, 2016a). The prevalence of CVD increases with age and
affects approximately 18% of Canadians 65 years and older (Statistics Canada,
2016a). In the province of Ontario, CVD was the listed cause for over 136,000
individuals requiring hospitalization in 2012, and contributed to over 24,000
deaths (Public Health Ontario, 2017). At the local level in Windsor-Essex,
Ontario, more than 4,000 annual hospital admissions and over 800 deaths per
year have been directly attributed to CVD (Public Health Ontario, 2017). These
statistics provide evidence of the tremendous impact CVD has in Canada from a
national, provincial and local perspective.
The potential for developing CVD can be individually influenced by various
modifiable and non-modifiable risk factors. Hypertension (HTN) is one such
modifiable risk factor and is the leading cause of CVD, and CVD-related mortality
(Ezzati et al., 2002; Daneai et al., 2011; Joffres et al., 2013; Benjamin et al.,
2017). HTN accounts for 50% of strokes and 49% of heart attacks globally
(Padwal et al., 2016). In Canada, the burden of HTN is high from both a human
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and an economic perspective. For example, a population-based study involving
26 million Canadian adults found that all-cause mortality was consistently higher
in people of any age who had HTN (Robitaille et al., 2012). Consequently,
mortality was 2 to 4 times greater in those aged 20-49 years with HTN, and
almost 2-fold greater in those aged 50 years and older with HTN (Robitaille et al.,
2012). In 2010, Canada spent approximately 14 billion dollars on HTN-related
medical care, equating to over 10% of Canada’s overall healthcare costs
(Weaver et al., 2015). This expense is projected to increase to over 20 billion
dollars by the year 2020 (Weaver et al. 2015). With this projection date only two
years in the future, increased understanding of HTN and approaches to reduce
the associated prevalence are crucial and timely.
1.2 Hypertension
Blood pressure (BP) is essential to maintain the supply of oxygen-rich
blood to working tissues by the arterial system (Tortora, G. J., & Nielsen, M.,
2009; McArdle et al., 2010). Arterial BP represents the force exerted by blood on
the walls of the arteries during systole (contraction phase of the heart; systolic
blood pressure or SBP) and diastole (relaxation phase of the heart; diastolic
blood pressure or DBP) after a contraction of the heart muscle (McArdle et al.,
2010; Waghmare & Srivastava, 2016). Chronically high BP, or HTN, increases
the force exerted on the arterial walls, which strains the cardiovascular system
(McArdle et al., 2010), and contributes to neural, hormonal, and vascular
dysfunction (Beevers et al., 2001; discussed in Section 1.2.2 on pg. 12). In brief,
HTN contributes to over-activity of the sympathetic nervous system (SNS),
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increased sodium and water retention, increased vasoconstriction, and increases
in blood vessel rigidity (Flammer & Luscher, 2010; El Assar et al., 2013; Thomas
& Dasgupta, 2015; see Section 1.2.3 on pg. 25). Over time, HTN can cause
damage to arterial vessels, contributing to increased risk for CVD development
and a reduced quality of life (McArdle et al., 2010).
Hypertension (HTN) is a global epidemic and in Canada, is the most
common chronic condition seen in primary care (WHO, 2013; Finley et al., 2018).
In Canada, approximately 7.5 million people are living with HTN, which equates
to 1 in 5 adults (Hypertension Canada, 2018). This is a troublesome number as 1
in 5 Canadian adults are also unaware they are living with HTN (Hypertension
Canada, 2018). In Ontario during the year 2014, residents with high BP
comprised 18.5% of the population, which was higher than the national average
of 17.7% (Statistics Canada, 2015a). Similar to CVD, HTN is also more
prominent with age, which is concerning as the average age of Ontario’s
population is 39.8 years, with 14.6% of the population older than the age of 65
years (Statistics Canada, 2015a). By the year 2036, it is projected that older
adults (defined as 65 years of age and older) will account for 25% of the
population. As HTN occurs at a higher rate in older adults, this may have the
potential to result in a higher incidence of people with HTN, impacting Ontarians,
and ultimately Canada’s, future (Statistics Canada, 2015a). With HTN presently
afflicting 1 in 5 people globally, and contributing to 9.4 million deaths related to
complications with HTN, prevention and management strategies have come to
the forefront in reducing CVD and CVD-related death worldwide (WHO, 2018a).
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To understand why an individual may have high BP, HTN can be divided
by root cause as either primary (essential) HTN or secondary (non-essential)
HTN (Noel & Demper, 1994). Primary HTN accounts for approximately 95% of all
cases of HTN and is heterogeneous in nature, with each individual having no
definitive cause for high BP (Carretaro & Oparil, 2000). Secondary HTN is
associated with specific conditions such as renal, adrenal, or hormonal disorders
that cause sustained BP, and in these instances treatment of these conditions
usually returns BP to a normal state (Viera & Neutze, 2010).
In both instances, strong relationships exist between high resting BP
values and the risk of CVD, renal disease, and mortality (Carretero & Oparil,
2000). Evidence has suggested there is a linear relationship between BP and the
incidence of stroke (Lawes et al., 2004; Ishikawa et al., 2007), where a higher
level of BP would then increase the risk of incidence. Resting BP values below
120 mmHg SBP and 80 mmHg DBP are considered within a normal range
(McArdle et al., 2010; Leung et al., 2017; Nerenberg et al., 2018). Although
continually evolving, HTN has traditionally been defined as having a resting BP of
≥140/90 mmHg when using non-automated devices (e.g. sphygmomanometer)
(Leung et al., 2017; Nerenberg et al., 2018). Recently, guidelines have included a
≥135/85 mmHg cut-off when using automated office blood pressure (AOBP)
devices (Leung et al., 2017; Nerenberg et al., 2018). HTN can be further
classified by stages. For years, the stages of HTN have been described as:
Stage 1 HTN as 140-159/90-99 mmHg and Stage 2 HTN as >160/100 mmHg
(Daskalopoulou et al. 2015). However, the American College of
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Cardiology/American Heart Association (ACC/AHA) have recently defined more
conservative stages of HTN: Elevated (120-129/<80 mmHg), Stage 1 HTN (130139/80-89 mmHg), and Stage 2 HTN (≥140/≥90 mmHg, Whelton et al., 2018). It
is unclear if these newly recommended stages will gain global support.
Although previous guidelines have used the non-automated range for
diagnosis, accumulating evidence supports the use of AOBP values ≥135/85
mmHg as a more appropriate diagnostic guideline for HTN (Mancia et al., 2013;
James et al., 2014; Leung et al., 2017; Nerenberg et al., 2018; Whelton et al.,
2018). Additionally, there is growing evidence to support ambulatory BP as a
superior tool for diagnosis, as it measures BP over a 24-hour period (daytime:
6am to 10pm, nighttime: 10pm to 6am, mean 24-hour) (Pickering et al., 2005;
Leung et al., 2017; Nerenberg et al., 2018). Using ambulatory measures, HTN is
defined as mean awake BP of ≥135/85 mmHg or mean 24-hour BP of ≥130/80
mmHg (Leung et al., 2017; Nerenberg et al., 2018). Most individuals will have
their highest pressures in the morning and lowest pressures at night, with the
onset of sleep, decreasing BP by decreasing metabolic activity (Pickering, 1990).
These BP measures taken at night can be used to examine “dipping status”
(explained further in Section 1.2.1 on pg.7), or the gradual decrease in BP seen
at the onset of sleep, where dipping <10% of their awake BP average would be
classified as non-dipping (Pickering, 1990; Mancia & Verdecchia, 2015). This
phenomenon of non-dipping has been shown to be present in hypertensive
individuals and is associated with sleep apnea, diabetes, congestive heart failure,
orthostatic hypotension, and Cushing’s syndrome (Pickering, 1990). While there
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are many advantages to ambulatory measurement, non-automated and
automated measures are common for clinical use as they are time and cost
efficient (Pickering et al., 2005).
1.2.1 Blood Pressure Measurement
As briefly mentioned in Section 1.2 above, BP measurement is integral to
the effective diagnosis and treatment of HTN. The most accurate measure is
completed via insertion of a catheter equipped with a transducer into the radial
artery measuring beat-to-beat systolic, diastolic, and mean arterial BP (Parati et
al., 1989). Although this procedure remains the most accurate method, it is both
costly and higher risk, requiring specialized training and personnel to perform
correctly (Parati et al., 1989). Alternatively, there are other methods of measuring
BP including: the non-automated method of auscultatory sphygmomanometry,
and automated oscillometric methods (Pickering et al., 2005). Each of these
methods involve occlusion of the brachial artery and are recommended in recent
guidelines for BP measurement (Dasgupta et al., 2014; Leung et al., 2017;
Nerenberg et al., 2018).
Auscultatory Sphygmomanometry
Auscultatory sphygmomanometry is used in office BP (OBP)
measurement and performed by placing a cuff around the arm and inflating the
cuff to a supra-SBP to collapse the brachial artery (Perloff et al., 1993). As the
cuff gradually deflates, the appearance and disappearance of sound generated
by arterial pulse waves, or Korotkoff sounds, determine the SBP and DBP,
respectively (Perloff et al., 1993; Pickering et al., 2005).
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There are several important limitations associated with this method that
may influence its accuracy. For example, the level of skill of the practitioner
identifying the Korotkoff sounds (Pickering et al., 2005), age-related hearing loss,
decreased focus over long shift periods, parallax error (where BP could be over
or underestimated based on the angle the practitioner is viewing the
sphygmomanometer (Williams et al., 2009), and observer biases (practitioner
altering results based on existing relationships) (Pickering et al., 2005; Sechrest
et al., 2005) all play a role in obtaining accurate measurements. The device itself
also has limitations, as cuffs that are larger in comparison to an individual’s arm
may need more pressure to cause occlusion, which can also impact results
(Sechrest et al., 2005). Although this method is convenient and time efficient, the
collective limitations can lead to a misdiagnosis or an undiagnosed case of HTN
(Pickering et al., 2005). Evidence has also shown that measurements taken via
auscultatory sphygmomanometry are typically higher on average compared to
automated methods (Myers et al., 2010). This may be due to white coat HTN, in
which the presence of a clinician will increase the patient’s BP unintentionally,
producing inaccurate readings of his or her true BP (Myers et al., 2010). This
phenomenon is mitigated by using both oscillometry and ambulatory BP methods
(Myers et al., 2010).
Oscillometry
Recently, oscillometric methods have become the preferred method for
measuring and assessing resting BP, contributing to the popularization of AOBP
measurement (Mancia et al., 2013). Similar to auscultatory sphygmomanometry,
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oscillometry also uses occlusion of the brachial artery by an inflatable cuff (Alpert
et al., 2014). However, a microprocessor within the device is used to detect the
SBP and DBP via oscillatory signals (Alpert et al., 2014). Oscillometry does not
involve the use of Korokoff sounds, but rather measures the amplitude of
oscillometric pulses from the brachial artery (Alpert et al., 2014). The cuff inflates
from 160 to 180 mmHg (for normotensive, inflation adjusts to be greater than
SBP) for an adult individual and will be deflated in a controlled release via a small
valve (Alpert et al., 2014). This controlled automated release then produces the
oscillatory signals, which the microprocessor uses to create an estimate for mean
arterial pressure (MAP) (Shahriari et al., 2003). Using the MAP in conjunction
with the built-in algorithms, SBP and DBP are determined (Shahriari et al., 2003).
HTN is determined at a lower range of ≥ 135/85 mmHg with this device due to
the accuracy when compared to auscultatory sphygmomanometry, and recently
this range has become a new diagnostic standard (Leung et al., 2017; Nerenberg
et al., 2018; Whelton et al., 2018). This method can also be used to reduce the
effects of white coat HTN (Myers et al., 2010; Myers et al., 2014). Home BP
measurement is now a unique testing method, whereby AOBP is determined
using a device in the patient’s own home by the patient themselves (Myers et al.,
2010; Myers et al., 2014). Research has shown that in both instances BP values
are commonly seen to be lower than when acquired in clinical settings (Myers et
al., 2010; Myers et al., 2014).
Although this method requires less training time and has fewer
interpersonal variations, a prominent concern is the variability between
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oscillometric devices as different manufacturers use differing algorithms
(Pickering et al., 2005; Alpert et al., 2014). As these specific algorithms are
undisclosed between companies, results may differ between one individual and
multiple AOBP models (Pickering et al., 2005; Alpert et al., 2014). Oscillometric
methods may also be impacted by different factors that may influence detection
of oscillometric signals within the cuff, one factor being arterial stiffness
prominent in older individuals and may underestimate MAP, ultimately impacting
SBP and DBP values (Pickering et al., 2005; Harvey et al., 2015). Another factor
that may impact potential diagnosis is incorporation of home BP monitoring. This
may also provide an accurate BP reading by reducing white coat HTN, as noted
above, but automated home models introduce reporting bias into the diagnosis
process (Myers et al., 2014). Reporting bias is when the patient responsible for
reporting their BP results does so incorrectly based on his or her intentions (e.g.
a patient who does not want to take HTN medication may report lower readings
vs. a patient who has concerns about HTN risks may embellish their readings)
(Myers et al., 2014). Reporting bias can be reduced via a machine that transmits
results directly to the office (Myers et al., 2014). However, this added feature
increases the cost effectiveness of home BP, which reduces the accessibility of
this method (Myers et al., 2014). Despite the limitations AOBP, when it is
compared to intra-arterial and auscultatory methods, in accordance with updated
guidelines, it is regarded as an accurate method of measuring BP (Pickering et
al., 2005; Alpert et al., 2014; Mancia et al., 2013; Leung et al., 2017; Nerenberg
et al., 2018).
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Ambulatory Blood Pressure
Unlike sphygmomanometry or oscillometry that are typically constrained to
a small number of readings in a clinical setting, ambulatory BP monitoring is used
to collect BP readings several times over a 24-hour period (Turner et al., 2015).
The measurement process is similar to the preceding methods as it involves a
cuff being placed around the upper arm to measure BP at the brachial artery
using oscillometric methods of BP calculation (O’Brien et al., 2001). The cuff is
then connected to a monitor by an inflationary hose, which is programmed to
measure BP (O’Brien et al., 2001). In this 24-hour period, BP is normally
assessed every 30 minutes during the day (6am to 10pm), and every hour during
night (10pm to 6am), which establishes BP means for different time periods (i.e.
full 24-hours, daytime BP, nighttime BP) (Pickering et al., 2005; Turner et al.,
2015). This continuous measure of BP provides a superior prediction of
cardiovascular risk when compared to the brief time periods measured from other
methods (Turner et al., 2015). This advantage can also be attributed to the BP
measurements being acquired during an individual’s daily activities, showing a
broader range of BP changes, and providing a truer representation of BP (Turner
et al., 2015). Nighttime measurements are of particular importance as, normally
(excluding those who work midnights, where these same hours are spent
awake), individuals will have a dip in BP from 10% to 20% of their average
daytime BP (Su et al., 2008; Turner et al., 2015). Those who dip less than 10%
are deemed “non-dippers” and are at a greater risk of developing HTN, sleep
apnea, diabetes, congestive heart failure, orthostatic hypotension, and Cushing’s
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syndrome (Pickering, 1990; Turner et al., 2015). This dip in BP is due to a
reduction in SNS activity and an increase in PNS function, which reduces plasma
epinephrine (E) and norepinephrine (NE) (Turner et al., 2015). However,
conditions like sleep apnea can stimulate greater sympathetic outflow due to a
lack of blood oxygen, which in turn increases BP by increasing SNS activity
(Fletcher, 2001). Ambulatory measurement can detect this increased diurnal BP,
providing evidence that BP measurement for 24-hour time periods provides a
greater understanding of an individual’s BP profile.
Ambulatory BP measurement has the benefit of portability allowing for the
collection of data outside of the clinical setting (Pickering et al., 2005). However,
this method does have its limitations. As ambulatory monitoring employs
oscillometry, as noted above, the algorithms for determining BP differ from
manufacturers (Pickering et al., 2005). Moreover, if an individual does not remain
still during each BP measurement completed, or if the individual removes the cuff
for bathing and reequips it incorrectly, insufficient results may be produced and
ultimately lead to an improper assessment (Pickering et al., 2015). Despite these
disadvantages, ambulatory BP measurement is superior in accuracy when
compared to traditional methods (Myers et al., 2010; Myers et al., 2014).
1.2.2 Blood Pressure Regulation
Before understanding elevated BP levels and HTN pathophysiology, it is
important to understand the mechanisms of BP control under normal conditions.
Cardiovascular homeostasis is maintained by the regulation of several key
physiological mechanisms including BP, amount of oxygen content within the
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blood, and blood volume (Dampney, 2016). Cardiovascular homeostasis is
important as it must be maintained to deliver oxygen to the working tissues
(Dampney, 2016).
To fully comprehend BP, the influencing components must be understood.
BP is the sum of cardiac output (Q) and total peripheral resistance (TPR; see
Equation 1), where, Q is the amount of blood pumped per contraction of the heart
and TPR is the resistance of the vessels to the flow of blood (Waghmare &
Srivastava, 2016). Cardiac output (Q) can be broken down further into stroke
volume (SV) and heart rate (HR), where SV is the amount of blood ejected by
each ventricle per contraction of the heart and HR is the number of heart beats
per minute (see Equation 2) (McArdle et al., 2010).
Equation 1: BP = Q x TPR
Equation 2: Q = SV x HR
Although BP may be broken down into the variables of Q and TPR,
numerous interrelated neural, hormonal and local pathways govern Q, TPR, HR,
and SV in an effort to maintain BP, and thus equilibrium (McArdle et al., 2010).
Neural Blood Pressure Regulation
BP is controlled neurologically by the autonomic nervous system (ANS),
which is comprised of the SNS and the parasympathetic nervous system (PNS)
(McArdle et al., 2010). Sympathetic nerves innervate the heart and blood
vessels, both of which are predominately regulated by sympathetic premotor
neurons located in the lower brain stem, while the hypothalamus and vagal
parasympathetic nerves innervate the heart and originate from the nucleus
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ambiguous in the medulla oblongata (Dampney, 2016). The purpose of the SNS
is to increase HR and myocardial contractility to facilitate an increase in SV,
increasing vasoconstriction to improve venous return, and increasing blood flow
to working tissues via vasoconstriction of the vascular beds of organs and
uninvolved tissue (Nobrega et al., 2014). The opposite is true of the PNS, as
activation causes a withdrawal of sympathetic activity, decreasing HR,
decreasing TPR, and vasodilation of vascular beds where BP was previously
reduced by vasoconstriction and SNS activity (Nobrega et al., 2014). For
example, during exercise, PNS activity is reduced to then increase SNS activity
to deliver oxygen-rich blood to working tissues by increases in HR, SV and TPR
(Nobrega et al., 2014).
Two key areas of the brain that co-ordinate ANS action are the central
command (CC) centre and the cardiovascular control centre (CCC) (Victor et al.,
1995). The CC will respond to cardiovascular stress via transmission of efferent
signals to the CCC (Michelini et al., 2015). Circulatory control is governed by two
principles: i) the CC sets the basic pattern of motor activity to skeletal muscles
and drives cardiorespiratory stimulation, and, ii) the feedback control
mechanisms are driven by intrinsic/extrinsic receptors from cardiovascular areas
and receptors within the active muscles and surrounding vasculature (Michelini et
al., 2015). At the onset of physical activity (e.g., limb movement related to shifting
from a seated position to standing), afferent signals from the body relay
information to the CC via a multitude of negative feedback loops (e.g. increases
in Q, changes in TPR, muscle contraction) (Michelini et al., 2015). The CC then
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activates the CCC, which alters activity to the nerves that innervate the heart and
blood vessels through sympathetic and parasympathetic mechanisms, ultimately
influencing BP (Michelini et al., 2015). To achieve this feedforward response, the
CC and CCC work in concert with feedback neural controllers located in the
periphery, which consist of baroreceptors, chemoreceptors, and skeletal muscle
receptors, to regulate BP (Michelini et al., 2015).
The baroreceptors are stretch receptors located in the walls of the carotid
sinus and aortic arch, which provide information regarding the BP in the vessels
entering the brain and leaving the heart (Wehrwein & Joyner, 2013; Dampney,
2016). Baroreceptors operate around a central point of BP (Osborn et al., 2005).
When the artery is distended beyond a set point, there is an increase in afferent
firing of signals to the CC (Wehrwein & Joyner, 2013). This signal is then relayed
by both the SNS (innervation of the blood vessels and heart), and the PNS
(innervation of the pacemaker cells of the sinoatrial node) (Wehrwein & Joyner,
2013). The response is made by the CCC to inhibit SNS activation, reducing
TPR, HR, and thus Q, and acting to ameliorate deviations from the central point
of BP (Taylor et al., 2014). This return of BP to the set-point range by SNS
suppression and PNS activation, slowing the heart and increasing vasodilation of
peripheral tissue is known as the arterial baroreflex (McArdle et al., 2010;
Dampney, 2016). Inversely, the opposite stimulus would elicit a similar response
by the arterial baroreflex. With a drop in BP, afferent signaling would cause the
CCC to increase SNS activation and PNS inhibition, increasing TPR, HR, and Q,
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thus increasing BP to the central point (Michelini et al., 2015; Dampney et al.,
2016).
Chemoreceptors are located in the carotid and aortic arteries and become
activated by a change in partial pressure of oxygen in the arterial blood (PaO2),
partial pressure of carbon dioxide in the blood (PaCO2), and pH content in the
blood (H+ ions) (Gordan et al., 2015; Dampney, 2016). For example, if there is a
drop in PaO2 and a rise in PaCO2 and H+ ions, the physiological response
through activation of this reflex is to increase respiratory rate and depth (to
increase alveolar ventilation) and increase BP to peripheral tissues that also
increase HR and Q to meet the demand of oxygen needed by those tissues
(Gordan et al., 2015; Dampney, 2016). An example of how chemoreceptor
activity occurs can be seen in sleep apnea (Fletcher, 2001). Sleep apnea is a
condition that reduces oxygen in the body during sleep caused by pauses in
breathing (Fletcher, 2001). As a result, chemoreceptors sense this decrease in
oxygen, which causes an increase of afferent signal firing to CC, and subsequent
CCC-generated increases in SNS activity (Fletcher et al., 2001; Gordan et al.,
2015). This enhanced SNS activity increases vasoconstriction of vascular beds
and ventilation to upregulate oxygen, thus increasing BP (Fletcher, 2001; Gordan
et al., 2015; Michelini et al., 2015).
There are also receptors located within skeletal muscle that help to control
BP. The two main afferent receptors in this location that have an influence on BP
are the type III mechanoreceptors and the type IV metaboreceptors (Leshnower
et al., 2001). Mechanoreceptors sense stretch and conformational changes in the
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arterial walls as a by-product of movement (similar to the baroreceptor)
(Leshnower et al., 2001). Metaboreceptors respond to the accumulation of
metabolic by-products of the working muscle such as lactic acid, potassium (K+),
bradykinin, serotonin, and adenosine (Leshnower et al., 2001). During
movement, muscle contractions cause stimulation of the mechanoreceptors, and
when the oxygen demands of the muscle are not met along with by-product
accumulation, metaboreceptors are activated (Belli et al., 2011). BP is controlled
by afferent impulses from these receptors being transmitted to the CC, which
then drives SNS to cause increases in ventilation and vasoconstriction of less
involved vascular beds (Leshnower et al., 2001; Belli et al., 2011). This in turn
will then cause a rise in BP through an increase in TPR, HR, and Q to meet
demands of working tissue (Belli et al., 2011).
Hormonal Control of Blood Pressure
Both the SNS and the PNS are involved with the release of hormones in
response to changes in BP homeostasis via parallel pathways. These hormones
include epinephrine (E), norepinephrine (NE), acetylcholine (ACh), vasopressin,
renin-angiotensin-aldosterone system (RAAS), and atrial natriuretic peptide
(ANP) (Gordan et al., 2015).
The main catecholamines that activate or deactivate sympathetic
receptors in the cardiovascular system are E and NE (Gordan et al., 2015).
These neurohormones accelerate sinoatrial node depolarization, causing the
heart to beat faster (tachycardia), along with increasing myocardial contractility
(McArdle et al., 2010). The force and rate of ventricular contraction will nearly
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double under maximum sympathetic stimulation (McArdle et al., 2010), efficiently
delivering oxygenated blood to working tissue. Postganglionic sympathetic nerve
fibres extend to the smooth muscle layers of small arteries, arterioles, and
precapillary sphincters located in target organs to regulate BP (McArdle et al.,
2010). These sympathetic nerve fibres contain E and NE receptors, that when
stimulated through binding of catecholamines, alter BP effectively (McArdle et al.,
2010). There are two types of E and NE receptors located in these areas to
induce changes, which are α-adrenergic and β-adrenergic receptors (Gordan et
al., 2015). The α-adrenergic receptor group are separated into α1-adrenergic
receptors located in most sympathetic target organs (excluding the heart), and
α2-adrenergic receptors found in synaptic junctions of SNS nerve endings of
vascular beds (Gordan et al., 2015). The β-adrenergic receptors are also
separated into two main types. β1-adrenergic receptors are located in the heart,
lungs, kidneys, and adipose tissue, while β2-adrenergic receptors are found in
most sympathetic organ targets (Gordan et al., 2015). Sympathetic stimulation of
α-1 and α2-adrenergic receptors induces vasoconstriction and stimulation of β2adrenergic receptors causes vasodilation (McArdle et al., 2010; Gordan et al.,
2015). Vasoconstriction and vasodilation manipulate the diameter of the blood
vessel to adjust TPR (McArdle et al., 2010; Gordan et al., 2015).
Vasoconstriction reduces the diameter of the blood vessel, increasing TPR and
BP, while vasodilation will increase the diameter of the blood vessel, facilitating
decreases in TPR and BP (McArdle et al., 2010).
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Unlike the SNS, the PNS promotes relaxation and vasodilation,
accomplished by release of the hormone ACh (McArdle et al., 2010). There are 5
different muscarinic receptor subtypes in the body, of these receptors, the M2
receptor is located in the heart and is the main binding site for ACh (Brodde et
al., 2001). Stimulation of the M2 receptor has both chronotropic (effects that
change HR) and inotropic effects (activation or deactivation of ion channels) in
the atria, but only inotropic effects in the ventricle (Brodde et al., 2001). A
decrease in HR occurs when ACh binds to the receptors on the sinoatrial node
(chronotropic) and the atrioventricular node (inotropic), causing an inhibitory
effect on adenyl cyclase, which then reduces intracellular cyclic AMP (cAMP)
(Brodde et al., 2001; McArdle et al., 2010). This interaction causes a reduction of
L-type calcium (Ca2+) current, which a constant influx of Ca2+ is needed for
contractions of the heart (Brodde et al., 2001). This reduction of cAMP by binding
of ACh is a regulatory mechanism of the PNS to reduce the force of contractions
in the heart, resulting in a decrease in HR, thereby lowering Q and BP (Brodde et
al., 2001). In this case, the purpose of the PNS is to reduce the sympathetic
effects of the catecholamines, bringing the body back to homeostasis, or normal
resting BP. This action is parallel to the baroreflex activity that occurs when there
is an increase in BP, as sensory information relayed to the CC then is transmitted
and acted upon by reducing SNS activity and increasing PNS activity.
Similar to the BP effects of E and NE, vasopressin will act to increase BP,
but through fluid retention. Vasopressin release is triggered by the baroreceptor
reflex (decrease in BP), chemoreceptors (decrease in blood oxygen), as well as
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decreases in blood volume (Japundzic-Zigon, 2013). Vasopressin affects the
kidney’s filtration system by increasing reabsorption of water in the collecting
tubules of the kidneys, effectively increasing blood volume, and thus, BP (Gordan
et al., 2015). Vasopressin’s action can be examined during exercise, as at higher
exercise intensities the body will sweat to reduce surface temperature, thus,
cooling the body (McArdle et al., 2010). In this instance, there may be significant
fluid volume loss, which increases blood viscosity and the potential for
dehydration (McArdle et al., 2010). Vasopressin is released to maintain adequate
fluid balance in blood and reduce the decreases in BP, blood volume, and
increases in plasma osmolality seen with sweating. BP to working tissues is thus
maintained by adequate fluid balance in combination with an increase in TPR by
vasoconstriction of major blood vessels (McArdle et al., 2010).
Parallel to vasopressin, the RAAS becomes active when the body is in a
state of hypovolemia and is triggered by a series of actions as followed: when
baroreceptors detect a decrease in BP (in this case from reduced blood volume),
when there is a decrease in blood concentrations of sodium chloride (i.e., salt),
and, when there is a lowered rate of blood flow through the macula densa
(located in the ascending loop of Henle just before the transition to the distal
convoluted tubule in the kidney) (Gordan et al., 2015). The onset of decreased
blood volume triggers the release of renin by the kidneys to transform
angiotensinogen into angiotensin I, which is then converted into angiotensin II via
angiotensin converting enzyme (Gordan et al., 2015). The product of angiotensin
II is important as it has a direct effect on the cardiovascular system (Fyhrquist &

20

Saijonmaa, 2008). Angiotensin II stimulates angiotensin type 1 (AT1) and type 2
(AT2) receptors to alter BP (Mehta & Griendling, 2007; Fyhrquist & Saijonmaa,
2008). Activation of AT1 receptors is associated with sympathetic activation and
release of E and NE, as it causes a generalized vasoconstriction, increasing TPR
in the renal arteries and the afferent/efferent arterioles (Gordan et al., 2015).
Angiotensin 1 (AT1) vasoconstriction is most dominant in arteries to the internal
organs, diverting blood to skeletal muscle for increased oxygen delivery (Gordan
et al., 2015). Angiotensin 1 (AT1) stimulation also increases sodium (Na+)
reabsorption (which passively acts on water reabsorption) and is the precursor to
aldosterone release from the adrenal cortex, which also increases Na+ intake
(Mehta & Griendling, 2007). This increase in TPR via vasoconstriction combined
with an increase in blood volume by sodium and fluid retention will cause a rise in
BP. However, in contrast, when angiotensin II is bound to AT2 it counterbalances
the effects of AT1, as AT1 is excitatory and AT2 is inhibitory. Angiotensin II is
more likely to bind to AT2 receptors at higher blood concentrations, which
stimulation will cause vasodilation, thought to be predominantly caused by nitric
oxide (NO) release (a potent vasodilator discussed in further detail below) (Mehta
& Griendling, 2007; Fyhrquist & Saijonmaa, 2008; Carey & Padia, 2013).
Research regarding AT2 is relatively new when compared with that of AT1.
However, it is hypothesized that AT2 receptors play a large role in natriuresis and
diuresis, or secretion of sodium and water, respectively, via the kidneys (Carey &
Padia, 2013). Equilibrium is maintained once angiotensin II has saturated AT1
receptors (Carey & Padia, 2013). It has also been theorized that angiotensin II
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could be converted to angiotensin III, which then binds to the AT2 receptor to
balance the effects of AT1 (Carey & Padia, 2013). Although research is growing
with regards to this topic, AT2 receptors need to be examined further to uncover
the true physiological effects.
Atrial natriuretic peptide (ANP) is secreted primarily from the atrial
myocytes in response to increased angiotensin II, β-adrenergic receptor
stimulation, and intravascular volume changes, which causes a localized stretch
on the walls of the atria sensed by mechanoreceptors (Brenner et al., 1990).
ANP secretion is also influenced by ACh, E and vasopressin (Brenner et al.,
1990). The central functions of ANP are to promote natriuresis and diuresis
(excretion of Na+ and water) in the kidneys, in combination with vasodilation to
reduce BP (Song et al., 2015). Vasodilatory properties of ANP can be observed
during hypoxia, as ANP will be secreted to increase oxygen delivery back to the
heart and to cause vasodilation in peripheral arteries to reduce BP (Dietz, 2005).
Natriuresis and diuresis is accomplished by ANP through increases of cyclic
guanosine monophosphate-dependent protein kinases (PKGs), which increases
glomerular filtration, inhibits sodium and water reabsorption, and suppresses
secretion of renin, which is the hormonal precursor for RAAS activation (Zeidel,
1990; Theilig & Wu, 2015). Decreases in Q are also related to ANP mediated
sympathetic and parasympathetic activity. ANP causes hypotension and
suppresses the stimulatory effects of baroreceptor activation, which then reduces
sympathetic activity and drives parasympathetic activity (Brenner et al., 1990).
Relaxation of vascular smooth muscle cells then occurs by lowering intracellular
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levels of Ca2+ and decreasing the vessel sensitivity to Ca2+, thus causing
vasodilation (Carvajal et al., 2000). In summary, ANP lowers BP by reducing
TPR through vasodilation of the peripheries and heart, excretion of sodium and
fluid (reducing the total blood volume), and via reductions in HR (Song et al.,
2015).
Local Control of Blood Pressure
Working tissues release substances that are produced via increased
metabolic demands, and these locally produced components help to regulate BP.
During neural and hormonal regulation mechanisms, metabolic by-products are
released from each pathway that may also aid in BP regulation locally (Beevers
et al., 2001). Endothelial cells release local agents in response to increases in
blood flow and shear stress caused by blood on vascular endothelium (McArdle
et al., 2010). These regulators function to alter smooth muscle diameter through
vasoconstriction and vasodilation and include: K+, NO, and endothelin-1 (ET-1),
which may all work simultaneously to maintain homeostasis (McArdle et al.,
2010).
Potassium (K+) is an abundant intracellular ion, which is used to create
action potentials in a neuron (Haddy et al., 2006). The Na+-K+-ATPase pump
helps to create action potentials by pumping K+ out of the plasma membrane and
Na+ into the membrane (Haddy et al., 2006). When a muscle tissue becomes
active, action potentials are created to meet the demands of the exercising
tissues (Haddy et al., 2006). Due to the unequal nature of the pump an
accumulation of K+ occurs resulting in hyperpolarization of the membrane
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(Haddy et al., 2006). In this instance, this hyperpolarization causes a reduced
Ca2+ influx into the cell, which then causes a dilation of the arteriole (Haddy et
al., 2006). When there is a reduction of Ca2+, the blood vessels in the
surrounding area have difficulties maintaining an increased TPR, as Ca2+ is
needed for the contraction of the endothelium (Haddy et al., 2006). TPR is then
reduced as vasodilation occurs in the area of increase K+ concentrations, which
reduces BP locally.
Nitric oxide (NO) is involved in various physiological processes and is
continually synthesized by two different NO synthases (NOS), which are
neuronal NOS (nNOS) and endothelial NOS (eNOS) (Lundberg et al., 2008;
Lundberg et al., 2015). L-Citruline and NO are formed by eNOS and specific
physiological cofactors (for example, reduced tetrahydrobiopterin or BH4) in the
endothelium as a response to mechanical stimuli (Lundberg et al., 2008;
Lundberg et al., 2015). NO diffuses into the underlying smooth muscle cells,
which then will generate cyclic guanosine monophosphate (cGMP) (Lundberg et
al., 2015). This process has a vital role in regulation of vascular tone and
endothelial integrity as it causes vasodilation (Lundberg et al., 2015). NO will
potentially pass through underlying cell membranes to neighbouring arterial walls
to expand the vasodilatory effects (McArdle et al., 2010). TPR is then modified by
increasing blood flow to tissues by gradually altering the arteriole size of
surrounding tissues, effectively reducing BP.
Endothelial cells release ET-1, a vasoconstrictor, which counterintuitively
is not stored in these cells (Chester & Yacoub, 2014). Release of ET-1 is
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dependent on mechanical stimulation (shear stress), hypoxia (reduced
environmental oxygen), reduced levels of estrogens, glucose, thrombin, and
competing vasoconstrictors (Chester & Yacoub, 2014). Factors that reduce the
synthesis of ET-1 include increases in NO, ANP, and estrogen (Chester &
Yacoub, 2014). Once synthesis of ET-1 occurs, ET-1 will bind to designated
receptors located on vascular smooth muscle cells (Chester & Yacoub, 2014).
ET-1 has three main binding sites in relation to BP regulation. When ET-1 binds
to ETA or ETB2 it causes vasoconstriction of the smooth muscle, increasing TPR
and BP (Gordan et al., 2015). When ET-1 is bound to ETB NO is released to
facilitate vasodilation and decrease TPR and BP (Gordan et al., 2015).
Vasoconstriction is also modulated through the stimulation of protein kinase C
(PKC), and through an influx of calcium into the cell to facilitate contraction of the
muscle (Chester & Yacoub, 2014).
1.2.3 Pathophysiology of Hypertension
Adequate BP control is reliant on the balance of Q and TPR with
increases in one or both factors leading to the development and maintenance of
HTN (Beevers et al., 2001). The specific mechanisms for these increases remain
unclear, and are likely multifaceted and complex. HTN development is
purportedly linked to dysfunction in one or more of the neural, hormonal, and
local mechanism(s) that regulate systemic BP, and enhanced via a plethora of
risk factors (Beevers et al., 2001).
From a neural perspective, SNS over activity has been implicated in the
development of primary HTN (Mancia et al., 1999; Beevers et al., 2001; Manolis
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& Poulimenos, 2014). Elevated SNS activity increases the likelihood of HTN
development through stimulatory effects on the cardiovascular system and
kidneys to create increases in Q and TPR (Parati & Esler, 2012). In persons with
established HTN, NE (see Section 1.2.2 for details, pg.12) is released in larger
amounts, binding to adrenergic receptors and maintaining HR in an elevated
state (Mancia et al., 1999), increasing Q and BP. Individuals with primary HTN
have a higher SNS activity level than their normotensive counterparts (Thomas &
Dasgupta, 2015). Grassi et al., (1998) demonstrated that with increasing stages
of HTN, there was a markedly increased level of SNS activity. Researchers
suggested that increased levels of plasma NE causes increased sympathetic
outflow to the heart and kidneys (Fischer & Paton, 2012; Parati & Elser, 2012;
Manolis & Poulimenos, 2014; Thomas & Dasgupta, 2015; Grassi & Ram, 2016).
This increased sympathetic outflow increases HR, Na+ retention, and water
retention via sympathetic denervation of the heart and renal tubules (Thomas &
Dasgupta, 2015).
Hypertension (HTN) is also a product of augmented sympathetic outflow
to the kidneys, which affects the RAAS system (Grassi & Ram, 2016). Increased
sympathetic activity to the juxtaglomerular cells cause an increase in renin
release, which increases angiotensin II and impairs renal vasodilation (Thomas &
Dasgupta, 2015; Grassi & Ram, 2016). This then upregulates aldosterone
release, altering BP by augmenting retention of Na+ and fluids (passively), which
together cause an increase in BP via vasoconstriction and elevated blood volume
(Beevers et al., 2001; Singh et al., 2010; Thomas & Dasgupta, 2015).
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At the local level, the endothelium can be examined as a contributor to
HTN. Endothelium is the inner most layer of the vascular wall, which healthy
endothelium is characterized by vasodilatory, anti-inflammatory, and antithrombotic responses as described previously (see Section 1.2.2 pg.12).
However, dysfunctional endothelium has a decreased response to local
regulators of BP, in particular, the prominent vasodilator NO (Flammer &
Luscher, 2010). This reduced efficacy affects vascular function by reducing
vasodilatory response, and this has been observed in hypertensives and those
with a family history of HTN (Panza et al., 1990; Taddei et al., 1992; Flammer &
Luscher, 2010).
A decreased bioavailability of NO, due to interaction with reactive oxygen
species (ROS), may also facilitate HTN development and maintenance (Flammer
& Luscher, 2010). Superoxide anion (O2-), which is a common form of ROS, can
then transform NO to peroxynitrite (ONOO-) to reduce the bioavailability of NO
(Spieker et al., 2000; Sindler et al, 2009; Harvey et al., 2015). Peroxynitrite
(ONOO-) oxidizes tetrahydrobiopterin (BH4), an essential cofactor (a substance
that is essential for an enzyme’s activity) for NO synthesis by eNOS, to an
inactive form effectively reducing NO production (Sindler et al., 2009; Harvey et
al., 2015). NO, as noted above, is a key factor for vasodilation as it modifies TPR
passively by interacting with arterial walls, and without this effect of NO, BP will
steadily increase as its availability is reduced (Sindler et al., 2009). However, this
is not the only culprit hypothesized to increase BP at the local level.
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Endothelin 1 (ET-1), a local vasoconstrictor to the endothelium (described
in Section 1.2.2 pg.12), may be increased in the plasma and is proposed to be
from increases in dietary salt, which increases the sensitivity of the renal tubules
to other stimuli that facilitate ET-1, like hypoxia (Heimlich et al., 2015). The
connection between a high dietary salt intake and the role of ET-1 increasing BP
has also been linked to the reduction of NO bioavailability through activation of
NADPH oxidase (NADPH oxidase is a membrane bound enzyme that transfers
electrons from the NADPH molecule that is a byproduct in energy production),
which also increases the production of ROS (Heimlich et al., 2015). Loomis et al.,
(2005) observed increased levels of ET-1 on rat aortic rings, which resulted in an
increase in O2- and provided evidence of reduced NO. This concept was further
tested by Heimlich et al., (2015), examining effects of high salt diets on mice,
which resulted in increases in renal ET-1 and NADPH oxidase activity causing an
increase in ROS (Babior, 1999). Thus, a decrease in NO bioavailability
contributes to increases in BP through a multifaceted system, although future
research involving human tissue may help to pinpoint exact mechanisms.
Vascular dysfunction can also be attributed to increased vascular
stiffness, which is a consequence of vascular remodeling (El Assar et al., 2013).
Remodeling occurs through both structural and functional changes of the
endothelium and smooth muscle cells, which cause disruption in communication
between these cell types (El Assar et al., 2013). Arterial stiffness is an outcome
of a decrease in arterial elasticity, facilitating an increase in BP (Zieman et al.,
2005; El Assar et al., 2013). Arterial walls contain a balance of collagen and
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elastin to maintain function, and over the course of the aging process elastin
fibers undergo fragmentation and thinning, which results in a transfer of
mechanical load and stress to collagen (100-1000 stiffer than elastin) (El Assar et
al., 2013). Through this process, stiffening of the artery occurs, causing an
overall increase in Q and TPR, which increases BP.
As noted above, numerous non-modifiable and modifiable factors increase
an individual’s lifetime risk of developing HTN. Non-modifiable risk factors are
those that cannot be manipulated to reduce the development of HTN, and
include: genetics/family history, age, sex, ethnicity, and environmental factors
(Maranon & Reckelhoff, 2013; Franceschini et al., 2014; Hicken et al., 2014;
Harvey et al., 2015). Unlike non-modifiable risk factors, potential modifiable
factors can be manipulated in order to decrease HTN development and
occurrence. Modifiable risk factors related to the development of HTN include:
obesity, diabetes mellitus, and tobacco smoking (Padwal et al., 2001).
A gene carries specific information to form a trait, which is transferred from
parents to children in the formation of that organism (Reece et al., 2013).
Passing on these specific traits or conditions that determine an individual’s
genetic make-up (Reece et al., 2013). Abnormal BP control is a heritable trait
that may be passed through generations with genetic contribution to HTN ranging
from 30-50% (Franceschini et al., 2014). However, determining genes directly
responsible for HTN development has been challenging with exact genes
remaining elusive (Franceschini et al., 2014). Due to the complex nature of HTN,
it is possible that there is interplay between other genetic factors like age, race
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and sex that may provide possible explanations for HTN development
(Franceschini et al., 2014).
Aging is a major non-modifiable risk factor in the development of HTN,
and is associated with endothelial dysfunction, vascular remodeling, and
increased vascular stiffness (Najjar et al., 2005; Harvey et al., 2015). Aging
increases the likelihood of HTN at around age 45 years for men, and age 55
years for women (Statistics Canada, 2016b). In Canada, approximately 9% of
men and 6% of women aged 35-44 years have HTN (Statistics Canada, 2016b).
This increases to around 20% and 13% of men and women, respectively, at ages
45-54 years (Statistics Canada, 2016b). Prevalence of HTN becomes greater at
age 75 years and older, with half of men (approximately 49%) and of women
(approximately 55%) living with HTN (Statistics Canada, 2016b). The vascular
changes associated with aging are thought to lead to chronic elevations of BP,
including vascular remodeling, which occurs over the life span (El Assar et al.,
2013). Neural regulation also declines as we age, as muscarinic receptor activity
(discussed in Section 1.2.2, pg.12) is weakened resulting in a decrease in SNS
and PNS regulation of the heart (e.g. SNS modulation in times of stress to cause
a rise in HR and BP) (Lakatta, 2015). Consequently, there is an increased level
of plasma E and NE thought to engage these receptors in older individuals
compared to younger individuals, which when combined with the decrease in
clearance of the hormones, results in an increase in BP (Manolis & Poulimenos,
2014; Lakatta, 2015).
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Hypertension (HTN) development is different depending on the ethnicity of
the individual (Hicken et al., 2014). For example, research has suggested African
Americans are more likely to have HTN after age 45 years, be aware of their
condition, and receive treatment, but are less likely to reach target BP values
with treatment when compared to Caucasian Americans (Hertz et al., 2005;
Howard et al., 2017). Possible physiological explanations have been explored,
with some evidence suggesting that hypertensive African Americans have higher
levels of ET-1 when compared to hypertensive Caucasian Americans (Ergul et
al., 1996). Campia et al., (2004) highlighted that disparity in BP may be the result
of increased receptor sensitivity to ET-1 in combination with higher plasma levels
of ET-1 that may be creating elevations in BP. However, further study is needed
to truly understand this HTN disparity, with future research focusing on a
comparison of a broader range of ethnicities for a complete understanding.
Similarly, there are also differences that exist between men and women
regarding the development of HTN (Maranon & Reckelhoff, 2013). It has been
suggested that in young healthy women β-adrenergic mediated dilation is greater
in comparison to men, which provides some level of protection against SNS overactivity and contributes to this group having lower resting BP (Kneale et al., 2000;
Hart et al., 2012). Evidence indicates that this may be a reason why young
women are less likely to be diagnosed with HTN when compared to young men
of the same age (Hart et al., 2012). Specific mechanisms illuminating why βadrenergic receptor sensitivity is greater in women is unclear, although there is
work from animal models to support the notion that estrogen increases the
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receptor sensitivity (Hart et al., 2012). The absence of this protective component
has been observed in post-menopausal women, with reduced levels of circulating
estrogen related to a decrease in β-adrenergic receptor sensitivity (Hart et al.,
2012). In contrast, the hormone testosterone is also linked to differences in BP
that may occur between sexes, potentially explaining why men are at a higher
risk of developing HTN before the onset of menopause in women (where HTN
appears equal for both men and women) (Kienitz & Quinkler, 2008; Zimmerman
& Sullivan, 2013). For example, castration of spontaneously hypertensive male
rats resulted in a decrease in BP and when these animal models were then given
testosterone these observations become inversed (Kienitz & Quinkler, 2008).
Testosterone is suggested to increase synthesis of NE, in which case may lead
to an increase in SNS activity (Kienitz & Quinkler, 2008). However, research is
inconclusive on the HTN disparity between the sexes based on testosterone
levels, with evidence supporting reduced testosterone levels also associated with
HTN development (Kienitz & Quinkler, 2008; Hart et al., 2012; Zimmerman &
Sullivan, 2012). Future direction may include specialized treatment plans
according to ethnicity and sex of an individual to promote effective treatment
(Kienitz & Quinkler, 2008).
Unlike the previous factors, environmental elements are part of an
individual’s external living circumstances, but also contribute to HTN pathology to
compound previously mentioned morphology. Air pollution, referred to as
particulate matter (PM), has recently been studied, and related work provides
evidence that air-pollutants effect HTN development (Cosselman et al., 2015).
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Dvonch et al., (2009) examined the effects of ambient PM by daily BP
measurements on 347 residents of Detroit, Michigan over a two-year period.
Results of this study provided evidence that increased exposure to PM was
associated with increased BP. Specifically, for every 10-μ/m3increase in PM
there was also an increase in SBP of approximately 3 mmHg. Brook et al., (2014)
found similar results acutely, as adults exposed to 2-hour periods of PM, which
caused increases of 3-4 mmHg SBP. Speculated biological explanations include
SNS over activity, arterial vasoconstriction, and endothelial dysfunction (Franklin
et al., 2015). Although exact details of these biological mechanisms remain
elusive, the evidence provided suggests that air pollution is a major contributor to
the current HTN crisis, and is affected by both acute and chronic exposure
(Franklin et al. 2015).
With regards to obesity, a modifiable risk factor linked to HTN, higher
levels of fat mass have been associated with higher levels of SBP and DBP
(Leung et al., 2017; Nerenberg et al., 2018). In Canada, 30% of adults who were
classified as overweight or obese were also classified as being hypertensive,
compared to 12% of normal weight adults with HTN (Statistics Canada, 2015a).
Research has indicated that obesity is linked to over activity of the SNS, and
changes in renal Na+ and water retention (as discussed previously above)
(Rahmouni, 2014). These changes have been seen in animal models as
demonstrated by Armitage et al., (2012) by feeding a high fat diet to rabbits for a
time period of 3 weeks. Rabbits who were fed this high fat diet gained 504 grams
of excess fat over the 3-week test, which resulted in increased BP, HR, renal
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sympathetic nerve activity, and impaired baroreflex function (Armitage et al.,
2012). As with the Armitage et al., (2012) study, evidence has shown renal
sympathetic activity to be increased with obesity, altering BP further through fluid
and Na+ retention in the renal tubules (Rahmouni et al., 2014). Lohmeier et al.,
(2012) observed this phenomenon by baroreflex stimulation in dogs fed high fat
diets. When the dogs gained 50% of their original weight during feeding, marked
increases in BP, HR, MAP, and sodium retention were observed. However, when
baroreceptor activation by electrical stimulation was initiated, this induced state
of HTN disappeared, with reductions in plasma NE and reduced rates of sodium
reabsorption by the renal tubules. With these results in mind, control of excess
weight has been incorporated into current HTN guidelines (Leung et al., 2017;
Nerenberg et al., 2018) as a method of decreasing chances of HTN development
or reducing BP in hypertensive individuals (as discussed below in Section 1.2.4
Treatment, pg. 36). Excess weight is theoretically a modifiable risk factor as it
can be commonly mitigated by proper diet and exercise to cause fat-mass
reduction and an overall maintenance of more ideal body fat levels (McArdle et
al., 2010). However, there are other factors that may prevent weight from being a
completely modifiable factor as socioeconomic status may limit exercise and
proper nutrition, or hormonal imbalances may create a level of difficulty the
average person may not struggle with (Bhurosy & Jeewon, 2014; Mullur et al.,
2014).
Diabetes is characterized by a malfunction in the action of insulin, the
secretion of insulin, or both complications simultaneously, resulting in
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hyperglycemia (American Diabetes Association, 2014). Approximately 90-95% of
diabetes cases are classified as diabetes mellitus (also known as type 2
diabetes, or adult onset diabetes), which consists of decreased insulin sensitivity
and a relative insulin deficiency (American Diabetes Association, 2014). Although
direct causes of diabetes mellitus are unknown, increases of abdominal body fat
are commonly seen in those with a diagnosis, and ultimately, also contribute to
the development of HTN (American Diabetes Association, 2014). It is theorized
that an increase in SNS activity is linked to a greater chance of developing
diabetes mellitus and HTN, creating an overlap between diseases (Sowers,
2013). Oxidative stress and inflammation are increased with diabetes mellitus,
and these occur concomitant to a decreased bioavailability of NO (Cheung & Li,
2012; Sowers, 2013). This is accomplished through increases in SNS activity,
which causes increases in the RAAS system activity that is common in diabetics
(Cheung & Li, 2012). Malfunction in the endothelium may be due to
overstimulation of angiotensin II release, which in turn fosters ROS formation
reducing the effectiveness and bioavailability of NO (Cheung & Li, 2012). This
decreased bioavailability then causes a reduced ability for endothelial-mediated
vascular relaxation in the arteries, attenuating the capabilities of the body for
vasodilation, thus, causing arterial stiffness, and a chronically elevated BP
(Cheung & Li, 2012; Sowers, 2013). This can be characterized by a narrowing of
the blood vessels, which increases TPR and results in BP to be higher in diabetic
individuals (Sowers, 2013). Insulin resistance seen in type 2 diabetics is thought
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to increase the SNS, which leads to the increases in ROS and HTN (Cheung &
Li, 2012).
Tobacco smoking has also been identified by the World Health
Organization as a leading modifiable risk factor in developing HTN (WHO,
2018b). Smoking cigarettes increases arterial stiffness, thus increasing TPR and
BP (Kim et al., 2005). It also affects the cardiovascular system by means of two
toxic chemicals: nicotine, and carbon monoxide (Leone, 2015). Receptor binding
of nicotine stimulates the SNS through release of E and NE, effectively raising
HR and SBP (Leone, 2015). Nicotine also promotes endothelial dysfunction as it
causes a reduced bioavailability of NO through increased oxidative stress
(Leone, 2015). This reduction of NO reduces the endothelium’s capability of
vasodilation, and thus, contributes to an increase in BP (Leone, 2015). Carbon
monoxide also contributes to increases in BP by causing hypoxia (Leone, 2015).
Carbon monoxide is formed in the body when carbon binds to oxygen, and has
the potential to then bind to hemoglobin (Leone, 2015). Once carbon monoxide is
bound to hemoglobin, it forms carboxyhemoglobin reducing the efficiency of the
blood to deliver oxygen to tissues (Leone, 2015). Hypoxia, in this case, causes
an increase in HR and BP to adapt to this reduced efficiency in order to
accommodate the reduced oxygen at the tissue.
1.2.4 Treatment of Hypertension
The goal of HTN treatment is to lower elevated BP to within clinical target
ranges (Leung et al., 2017; Nerenberg et al., 2018). Although ever changing, it is
generally recommended that OBP is controlled to below 140 mmHg SBP and 90
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mmHg DBP, or ≤ 135 mmHg SBP and 85 mmHg DBP using AOBP or
ambulatory devices (WHO, 2013; Leung et al., 2017; Nerenberg et al., 2018).
The most recent AHA/ACC guidelines suggest a target for BP lowering to
<130/80 mmHg, which was based on the success seen in the Systolic Blood
Pressure Intervention Trial (SPRINT) study that incorporated targets of <120
mmHg (Ambrosius et al., 2014; Whelton et al., 2018). Currently, lifestyle
modifications and pharmacotherapy are cornerstone treatments for HTN
management.
The goal of lifestyle modifications is to recognize the condition(s) and
manage all other identifiable risk factors for HTN (Weber et al., 2014). Treatment
processes are usually a lifelong commitment, and termination of recommended
lifestyle changes or pharmaceutical prescriptions may be life threatening (Weber
et al., 2014). Endorsed lifestyle modifications include increasing physical activity,
weight reduction, decreasing alcohol consumption, following the Dietary
Approaches to Stopping HTN (DASH) diet, and an overall reduction of daily
stress (Leung et al., 2017; Nerenberg et al., 2018). With regards to physical
activity, the accumulation of 30-60 minutes of moderate intensity dynamic
exercise (e.g., walking, running, cycling, swimming) 4-7 days per week in
combination with daily activities is recommended to reduce BP (Leung et al.,
2017; Nerenberg et al., 2018). These guidelines are supported by
complementary guidelines around the world (Mancia et al., 2013, Weber et al.,
2014; Pescatello et al., 2015; Leung et al., 2017; Nerenberg et al., 2018; Whelton
et al., 2018). The 2017 AHA/ACC guidelines stress the importance of also
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incorporating dynamic resistance exercise and isometric resistance exercise into
exercise training programs for optimal BP control (Whelton et al., 2018). Dynamic
resistance exercise recommendations include 90-150 minutes of training at 50%80% of an individual’s 1 repetition maximum, with 3 sets per exercise, 10
repetitions per set, for at least 6 exercises total (Whelton et al., 2018). Decreases
seen in hypertensives following said dynamic resistance training
recommendations result in a BP reduction of approximately 4 mmHg (Whelton et
al., 2018). Additionally, isometric resistance training, which has recently been
added to the recommendations, employs an exercise program using a handgrip
dynamometer (discussed further in Section 1.3, pg. 44), completing 4, 2-minute
contractions at 30%-40% of an individual’s maximum voluntary contraction
(MVC), separated by 1-minute rest periods (Whelton et al., 2018). Training
should occur at least 3 times per week (Whelton et al., 2018). With regard to
diet, the DASH diet is a main recommendation for individuals living with HTN
(Sacks et al., 2001). The DASH diet puts emphasis on fruits, vegetables, low fat
dairy products, whole grains, poultry, fish, and nuts with small amounts of red
meats, sweets, and sugary snacks (Sacks et al., 2001).
Although these methods are effective, unfortunately many Canadians are
not meeting daily requirements for physical activity or diet (Statistics Canada,
2015b). This is exemplified by the fact that most Canadian’s waking hours are
sedentary 68% for men and 69% for women), and only 25% of the population are
accumulating 150 minutes of moderate to vigorous aerobic physical activity per
week as per the guidelines (Colley et al., 2018). Moreover, less than 40% of
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Canadians aged 12 years or older eat fruits or vegetables 5 or more times per
day (Statistics Canada, 2015b).
When lifestyle modifications are insufficient in lowering BP to within the
clinical target, pharmacological treatments are then prescribed along with
lifestyle-related treatments (Weber et al., 2014). Common medications
prescribed include angiotensin enzyme inhibitors, which reduce the conversion of
angiotensin I to angiotensin II, and angiotensin receptor blockers, which bind to
the receptor to prevent vasoconstriction by angiotensin II. Other medications
include thiazide and thiazide-like diuretics, which increase sodium excretion by
the kidneys; Ca2+ channel blockers, which block inward flow of Ca2+ ions
through the L channels of the arterial smooth muscle cells, lowering TPR and BP;
and β-blockers which prevent E from increasing HR and BP (Weber et al., 2014).
1.2.5 Exercise Training
Effects of Acute Aerobic Exercise on Blood Pressure
Acute exercise has the potential to lower resting BP levels post-exercise,
an occurrence named post-exercise hypotension (PEH) (Halliwill et al., 2014).
The effect has been observed for up to 22 hours after the completion of a bout of
aerobic exercise (Chen & Bonham, 2010; Halliwill et al., 2014); individuals with
higher pre-exercise levels experience the largest reductions (Syme et al., 2006).
In general, average reductions in BP following a bout of aerobic exercise for
normotensives and hypertensives are 8/9 mmHg and 10/7 mmHg SBP and DBP,
respectively (MacDonald, 2002).
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Although most PEH studies to date have involved resting BP as a primary
outcome, work by Ciolac et al., (2008) in post-menopausal women provided
evidence of 24-hour BP lowering after an acute bout of aerobic exercise.
Specifically, post-bout reductions in 24-hour SBP, 24-hour DBP, daytime SBP,
daytime DBP, nighttime SBP, and nighttime DBP were observed. Of interest, it
has been suggested that PEH may be a useful predictor for how an individual will
respond to chronic exercise training with BP-lowering (Ciolac et al., 2008).
Kiviniemi et al., (2015) demonstrated this concept by an acute aerobic exercise
test followed by a training protocol. Pre-training PEH-related decreases in SBP
was related to post-training reductions in resting SBP (Kiviniemi et al., 2015).
Although the potential mechanisms are elusive, it has been proposed that
the phenomenon can be explained by two different mechanisms. The first,
baroreceptor resetting (in which GABAergic interneurons exert less inhibitory
effects on barosensitive neurons, leading to a decrease in sympathetic outflow)
or the second, a sustained level of post-exercise vasodilation caused by
histamine receptor activation (Chen & Bonham, 2010; Halliwill et al., 2014).
Effects of Chronic Aerobic Exercise on Blood Pressure
Chronic effects of aerobic exercise have been extensively researched,
with concrete evidence for reductions in resting BP. Generally, research has
shown that aerobic exercise training interventions elicit average BP reductions of
approximately 2/2 mmHg and 7/5 mmHg for normotensives and hypertensives,
respectively (Cornelissen et al., 2013). Extensive research has been completed
to support the efficacy of aerobic training in lowering resting BP despite the
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multitude of modalities (walking, running, cycling, organized sport), intensities
(30-90% of maximal oxygen reserve), durations (30-60 minutes), and frequencies
(1-7 days per week) implemented (Pescatello et al., 2004; Lamina, 2010; Dimeo
et al., 2012; Krustrup et al., 2013; Arca et al., 2014; Börjesson et al., 2016).
The mechanisms responsible for BP reductions seen with chronic aerobic
exercise participation remain inconclusive, although it is speculated several
components are involved (e.g. neural, hormonal, local) and that reductions in BP
due to aerobic training can be attributed to changes to TPR rather than Q
(Pescatello et al., 2005). This also coincides with the notion that a decrease in
SNS activity due to aerobic training will increase vasodilation, effectively
decreasing TPR and BP (Pescatello et al., 2005). Aerobic exercise performed for
prolonged periods may reduce BP locally via reductions in ET-1 and ROS, while
increasing bioavailability of NO, which has recently been shown in animal models
during an 8-week training program (Maeda et al., 2001; Pescatello et al., 2004;
Braga et al., 2015; Wilson et al., 2016). Exercise induced anatomical adaptations
of the heart may also have an influence on BP, with aging endurance athletes
(65 years or older) having lower end systolic/diastolic volumes in both the left
ventricle and right ventricle in combination with similar increases in left ventricle
wall thickness seen in younger endurance athletes (Whyte et al., 2004; Wilson et
al., 2016).
There is a growing body of research examining the effects of chronic
aerobic training on ambulatory BP (Cardoso et al., 2010). Current meta-analysis
suggests an average reduction in daytime BP of approximately 3/3 mmHg and 3-

41

12/3-7 mmHg for normotensives and hypertensives, respectively (Gayda et al.,
2012; Cornelissen et al., 2013). Dimeo et al., (2012) demonstrated the effects of
an 8-week treadmill exercise program on 50 participants with resistant HTN,
where the use of 2 or more antihypertensive drugs were ineffective to lowering
BP alone. Completion of the protocol resulted in a decrease in daytime
ambulatory SBP and DBP.
Effects of Acute Dynamic Resistance Exercise on Blood Pressure
An acute bout of dynamic resistance exercise using large muscle groups
to lift weights through a series of dynamic movements produces immediate
increases in both SBP and DBP up to 400 mmHg and 200 mmHg, respectively
(MacDougall et al., 1985; Mayo et al., 1999). Intramuscular pressure created by
compression of the vasculature causes a drastic increase in TPR, which
increases in BP (Mayo et al., 1999).
Sympathetic nervous system (SNS) activity is also enhanced, increasing
NE secretion to augment HR and BP and provide adequate amounts of
oxygenated blood to working tissues (Mayo et al., 1999; Kraemer & Ratamess,
2005). However, the intensity of the working muscle activated and the amount of
muscle mass that is activated proportionally determines the increase in BP to the
acute bout of dynamic resistance exercise (Mayo et al., 1999). BP is also linked
to the phase of the lift, where the onset of the lifting phase will increase BP to
maximal levels, followed by a decrease in BP once the lift is completed, and an
increased BP level during the lowering phase of a lift (MacDonald, 2002).
Similar to acute aerobic exercise, evidence suggests that PEH occurs
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after an acute bout of dynamic resistance exercise, with limited research
involving ambulatory BP methods (Pescatello et al., 2004; Cardoso et al., 2010).
Melo et al., (2006) conducted experiments using a low-intensity strength training
protocol on medicated hypertensive women aged 41-50 years (n= 11, resting BP
= <160 mmHg/ 105 mmHg). Participants underwent low intensity resistance
exercise performed in a random order with an interval of at least 7 days.
Ambulatory BP was taken, with awake SBP, and DBP significantly lower in
exercise groups compared to control groups, with 21-hour readings yielding a
drop from approximately 128 mmHg/ 80 mmHg to 123 mmHg/76 mmHg,
respectively. Simão et al., (2005) also examined hypotensive effects after acute
resistance exercise with varying intensity, varying volume, and alternate training
methods. After each training session, participants were outfitted with ambulatory
BP monitors to determine post-exercise BP. The major finding of the study was
PEH response duration may be related to resistance exercise training volume at
high intensities, with PEH occurring for 60 minutes after 6 exercises and 50
minutes after 5 exercises. Recent meta-analysis research indicates PEH occurs
60-90 minutes post-exercise, with BP reductions proportional to pre-exercise
values, and larger muscle groups eliciting a greater PEH response (Casonatto et
al., 2016). These findings do coincide with previous research; therefore, continual
study of this phenomenon must be completed in order to fully understand the
mechanisms behind PEH following a bout of dynamic resistance exercise (Simão
et al., 2005; Melo et al., 2006).
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Effects of Chronic Dynamic Resistance Exercise on Blood Pressure
The literature regarding dynamic resistance training on BP is not as
extensive as it is with aerobic training (Cardoso et al., 2010). A meta-analysis
exploring randomized controlled trials of dynamic resistance training lasting at
least 4 weeks facilitated SBP and DBP reductions of 4 mmHg in normotensives
and 4/2 mmHg in hypertensives (Cornelissen et al., 2011). The latter results
(hypertensives) findings were not statistically significant, but this may be due to
the small body of work completed in the field (Cornelissen et al., 2011). However,
more recent research conducted by Mota et al., (2013) investigated the effects of
prolonged training on older adult, hypertensive women (n=64). Exercise sessions
were conducted three times per week for 16 weeks with increasing load (Month
1: light intensity; Month 2: 60% 1RM; Month 3: 70% 1RM; and Month 4: 80% 1
RM). Results showed an approximate difference in SBP of 14 mmHg and DBP of
4 mmHg. Moreira et al., (2016) then completed a study of similar design on 20
medicated hypertensive women over the age of 60 years with 12 weeks of
incremental dynamic resistance training. As with previous work, higher baseline
BP was related to high acute BP responses, which then manifested as a greater
BP lowering response to prolonged resistance training. Results of these studies
indicate that PEH response seen acutely is related to long term effects of
resistance training, similar to aerobic exercise (Moreira et al., 2016). However,
whether the mechanisms are the same is still unclear.
Currently, there is limited research with regards to the ambulatory BPlowering effects of dynamic resistance training, but the data to date suggests a
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lack of effect (Blumenthal et al.,1991; Pescatello et al., 2004; Cardoso et al.,
2010).
1.3 Isometric Resistance Exercise
A more novel intervention in the field of HTN management is isometric
resistance training, in particular isometric handgrip (IHG) training. IHG training
has emerged as a promising strategy that may be especially effective for
reducing BP in individuals who have difficulty managing their HTN (Brook et al.,
2013; McGowan et al., 2017). A typical IHG protocol involves the use of a
computerized handgrip dynamometer with participants performing 4, 2-minute
sustained squeezes (isometric contractions), each separated by 1-minute rest
intervals (Badrov et al., 2013). The 2-minute isometric contractions are
performed at 30% of an individual’s MVC and most often completed bilaterally
(Brook et al., 2013; McGowan et al., 2017). The individual is usually guided
through the described process via onscreen instructions and prompts displayed
on the computerized handgrip dynamometer. IHG training is typically performed
3-5 times per week for 8-10 weeks (Brook et al., 2013; Millar et al., 2014; Inder et
al., 2016; McGowan et al., 2017). Reductions in resting BP due to IHG training
have been noted in a wide array of individuals ranging from young adults (18-30
years) to older adults (>60 years), including those with and without HTN
(McGowan et al., 2007; Badrov et al., 2013; Millar et al., 2014; Inder et al., 2016).
After years of accumulating evidence supporting the effectiveness of IHG training
in BP control, the ACC/AHA supports its use as a treatment for HTN
management, and cites it as a “Best Proven Nonpharmacological Interventions
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for Prevention and Treatment of Hypertension” in their most recent guidelines
(Whelton et al., 2018). The CHEP are less specific in their recommendation, and
acknowledge a lack of adverse effects with handgrip training (Brook et al., 2013;
Leung et al., 2017; Nerenberg et al., 2018; Whelton et al., 2018). This type of
treatment may also bridge the gap for individuals who are incapable of
participating in or sustaining aerobic or dynamic resistance exercise-based
treatments, and may be a remedy for the growing burden of HTN in low-middle
income countries (Carlson et al., 2014).
Effects of Acute Isometric Handgrip on Blood Pressure
During an isometric muscle contraction, the underlying vasculature
becomes compressed and occlusion of blood flow occurs (Smith et al., 2005).
This reduced blood flow causes an accumulation of local metabolites (lactate,
adenosine triphosphate, K+, and H+), which activates a mechanism known as
the exercise pressor reflex (EPR) (Smith et al., 2005). SNS activity is then
increased by the EPR relaying afferent signals to the CC, thus increasing HR and
ultimately blood flow to the working tissues (Smith et al., 2005). Although
definitive mechanisms as to how IHG affects BP remain unclear, the BP lowering
effects have been documented through many studies. Current data supports only
modest and transient increases in SBP and DBP (∆ 12-38/7-23 mmHg) during
the contraction phase of the traditional IHG protocol (4, 2-minute isometric
contractions each separated by 1-minute rest intervals) for most people studied
thus far, even in those with HTN (Wiley et al., 1992; McGowan et al., 2006; Millar
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et al., 2009; Araujo et al., 2011; Millar et al., 2014; McGowan et al., 2017; Smart
et al., 2017).
The effects of an acute bout of IHG exercise on PEH are underinvestigated. Millar et al., (2009) and Araujo et al., (2011) had both observed
PEH following 4, 2-minute sustained isometric contractions at 30% of the
participant’s MVC with 1-minute rest periods in between each contraction, with
PEH of -3 mmHg SBP in older normotensive individuals and -12 mmHg SBP/-11
mmHg DBP in young normotensives. In contrast, Bartol et al., (2012) did not
observe PEH following an acute IHG bout in a population of well controlled,
medicated hypertensives, either at baseline or following an additional 8 weeks of
3X/week IHG training. However, results of this study may have been impacted by
the medication regimens of the participants. Similarly, Olher et al., (2013) did not
find any instance of PEH after acute bouts of IHG at any intensity in a similar
cohort of individuals medicated for HTN. Ash et al., (2017) investigated the
antihypertensive effects of both acute aerobic sessions and acute IHG sessions
in middle aged adults with prehypertension and obesity, and only observed PEH
following the aerobic exercise bout. However, it is important to note that the
amount of time engaged in aerobic exercise was far greater to be appropriately
compared, and the IHG group was under-powered statistically. Further
investigation is needed to fully understand the interaction between varying
populations, differing IHG methods, and intensities with regards to PEH.
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Effects of Chronic Isometric Handgrip on Blood Pressure
The most current meta-analysis of randomized trials cites average posttraining BP reductions of 5/4 mmHg, with greater reductions seen in individuals
with HTN (Inder et al., 2016). However, there is evidence that inter-individual
differences may occur with this type of training. Work from Millar et al., (2008)
suggested post-menopausal women experienced greater post-training BP
reductions in comparison to men of a similar age. In general, the small overall
number of women that have participated in IHG training trials to date make the
effects of sex difficult to ascertain (McGowan et al., 2017). With respect to age,
the most recent meta-analyses data provided evidence that adults > 45 years of
age experience larger reductions in MAP than those < 45 years of age (Inder et
al., 2016). Individuals with high pre-training SBP reactivity to math and isometric
contraction stress tasks also appear highly responsive to IHG training (McGowan
et al., 2017; Somani et al., 2017).
There is a lack of research regarding duration, intensity, and volume of
training (Lawrence et al., 2015), yet training for ≥ 8 weeks appears to elicit larger
reductions in SBP (7 mmHg vs. 3 mmHg), although there is no difference seen in
DBP when making this comparison (Inder et al., 2016). In Wiley et al., (1992), the
first of two studies consisted of testing IHG on subjects with high-normal resting
DBP, performing the isometric handgrip contractions for 2-minutes at 30% of an
MVC, with a 3-minute rest between each set of 2-minute contractions, 3 days per
week for 8 weeks. Training resulted in a decline of both SBP and DBP of
approximately 13 mmHg and 15 mmHg, respectively. In the second study,
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borderline hypertensive participants were chosen to complete 4, 45 second
contractions at 50% MVC with 1-minute rest intervals between contractions, 5
days per week for 5 weeks. Training resulted in significant reductions in SBP and
DBP pressure of 10 mmHg and 9 mmHg, respectively. Badrov et al., (2013)
investigated the effects of IHG volume on BP-lowering effectiveness in
normotensive women. Participants were either categorized into IHG3 or IHG5,
which consisted of training 4, 2-minute contractions at 30% MVC for either 3
times per week or 5 times per week for 8 weeks. Both groups had similar
reductions in SBP (6 mmHg), yet the IHG5 group achieved significant BP
reductions after 4 weeks of training, while the IHG3 group only showed these
reductions after 8 weeks of training.
Although only IHG training appears in current BP-lowering guidelines
(Leung et al., 2017; Nerenberg et al., 2018; Whelton et al., 2018), there is
evidence to suggest that isometric leg (IL) training elicits similar BP-lowering
benefits, although much of the work has been conducted in normotensive
populations. Previous experimentation has involved a general practice of double
leg contractions based on 20-50% of the individuals MVC, consisting of 4, 2minute isometric contractions separated by 3-minute rest periods, taking place 3
times per week for up to 4-8 weeks (Gill et al., 2015). Devereux et al., (2010)
demonstrated that 4 weeks of IL training reduced SBP and DBP by 5 mmHg and
3 mmHg, respectively, in a cohort of young healthy adults.
With respect to investigations involving exercise intensity and BP-lowering
effect, Wiles et al., (2010) investigated intensity levels of IL training on BP.
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Participants (n=33) were divided into control, high intensity (20% MVC), or low
intensity (10% MVC) grouping, which required IL training (4, 2-minute isometric
contractions separated by 1-minute recovery) 3 times per week for 8 weeks.
Changes seen in resting BP were significant for high intensity and for low
intensity, systolic, diastolic, and MAP. This demonstrated that lowering BP can
be achieved at a wide range of intensities when using IL protocols. Baross et al.,
(2012) then replicated this study using 14% MVC for the high intensity group and
8% MVC for the low intensity group. Significant changes in BP (MAP and SBP)
were only seen in the high intensity group after training.
The mechanisms responsible for the demonstrated reductions in BP
following IHG training remain unclear. As noted previously, HTN is associated
with dysfunctional vagal HR modulation, increased SNS activity and vascular
dysfunction (Anderson et al., 1989; Singh et al., 1998; Faulx et al., 2003). Work
to date supports improved vagal control of HR (Taylor et al., 2003; Millar et al.,
2014), reduced sympathetic activity (Taylor et al., 2003) augmented arterial
compliance and vascular function (McGowan et al., 2006, McGowan et al., 2007;
Badrov et al., 2013; Millar et al., 2014), enhanced oxidative capacity (Peters, et
al., 2006), and reduced Q (Wiles et al., 2017) as potential contributors to the BPlowering effects of IHG training.
1.4 Alternative Devices: Stress Ball
Although the benefits of IHG training have been documented as described
above, the high cost of the computerized IHG dynamometer employed (> $699
CAD; Zona Health, 2018) and lack of insurance coverage for the device creates
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an economic barrier to its implementation (McGowan et al., 2017). Previous
studies have identified the importance of developing cost-effective alternative
devices or techniques as a method of broadening isometric resistance training as
a viable treatment option for individuals with HTN (Millar et al., 2008; Zhang et
al., 2014; Wiles et al., 2017). The WHO has also endorsed the implementation of
cost effective, efficient, and innovative ways to reduce BP (WHO, 2017).
Early evidence suggests that alternative and affordable
devices/techniques elicit short-term training-induced reductions in BP. With
respect to IHG training, Millar et al., (2008) provided support for the BP-lowering
effects of a spring-loaded IHG device in normotensive older adults. Participants
who trained 3 times per week for 8 weeks at an intensity ranging from 15 to 30
pounds of force (depending on their baseline maximum force or MVC),
experienced post-training SBP and DBP reductions of 10 mmHg and 2 mmHg,
yet no changes were observed in the control group. This study provided the first
evidence to suggest IHG training with a cost-effective device can elicit the same
results. However, it is unclear if these results are generalizable to younger
normotensive or older hypertensive cohorts, or if they can be replicated using
other low-cost devices.
Similarly, Wiles et al., (2017) investigated cost effective methods of IL by
the effects of a 3 times per week wall squat (4, 2-minute bouts at 95% of HRpeak,
with 2-minute rest between bouts) 4 week training program on resting BP in
young, normotensive men. Post-training reductions in SBP (4 mmHg), DBP
(3mmHg), and MAP (3 mmHg) were observed. Although this method meets a
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cost-effective model for isometric training, it does not meet feasibility due to the
required lower limb strength that is necessary for participation. Thus costeffective, widely available options must continually be explored to find the best
option for isometric training.
An alternative and even less expensive device than the spring-loaded
device previously investigated (Millar et al., 2008), one not reliant on calibration
equipment to regulate force, and one that can be performed by individuals with
mobility issues, balance issues, or barriers that may prevent exercise involving
lower extremities is the widely known “stress ball”. Recent work by Morrin et al.,
(2018) lay a foundation for designing effective IHG protocols on noncomputerized, non-spring-loaded devices. Using a pre-HTN and HTN cohort, it
was demonstrated that a perceived exertion (CR-10) of 6 during a 2-minute IHG
contraction is equivalent to approximately 30% MVC (Morrin et al., 2018). To
date, no study has investigated the acute (during a bout) or chronic (training)
effects of IHG on BP or other indices of cardiovascular and psychophysical
function when using a stress ball.
1.5 Summary
HTN is the leading cause of CVD-related mortality, making it a substantial
contributor to global disease burden (WHO, 2017). With the number of CVDrelated deaths increasing each year (WHO, 2017), effective BP control is
essential, and a critical public health concern. The prevention and successful
treatment of HTN is now a global health priority of the WHO (WHO, 2013).
Current HTN treatment options include: reduction in excess body fat, cessation of
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smoking, changes in diet (DASH diet), increases in physical exercise (following
guideline recommendations), and pharmacotherapy (Nerenberg et al., 2018;
Whelton et al., 2018).
Despite these published widespread recommendations, successful BP
control is suboptimal, creating a need for new, innovative, time efficient, and
cost-effective methods to reduce HTN (Newson & Kemps, 2007; WHO, 2017).
IHG training is one such method, and has been recently endorsed by governing
bodies for BP management (Nerenberg et al., 2018; Whelton et al., 2018).
However, most isometric resistance training protocols present barriers limiting
their use – whether it be expensive hand or leg dynamometer devices, difficult to
calibrate spring-loaded IHG devices, or challenging wall squats. As such, longterm application of isometric resistance training as a BP-lowering treatment is
unlikely for many individuals in North America and worldwide (Millar et al., 2011;
Zona Health, 2018). As IHG training, and not IL training, is the endorsed method
of training, exploring inexpensive and widely available IHG alternatives, such as
the “stress ball” should be a priority. The enhanced feasibility, low maintenance,
and inexpensive nature (approximately $4 CAD) of the stress ball aligns with the
global (WHO, 2017) emphasis on reducing barriers to effective BP management.
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Chapter 2:
Getting the Best GRIP on Blood Pressure Control: Are Stress Balls and
Computerized Handgrips Equally Effective?

2.1 Introduction
Cardiovascular disease (CVD) is the number one cause of death globally
(WHO, 2017). In 2016, over 17 million or 31% of all global deaths were attributed
to CVD (WHO, 2017). Hypertension (HTN; traditionally defined as resting blood
pressure (BP) ≥140/90 mmHg; Gee et al., 2014; Nerenberg et al., 2018; Whelton
et al., 2018; Williams et al., 2018) is the leading cause of CVD and CVD-related
mortality, and the number one modifiable risk factor (Ezzati et al., 2002; Daneai
et al., 2011; Joffres et al., 2013; Benjamin et al., 2017). Already affecting more
than 1 billion people worldwide (Fisher & Curfman, 2018), the World Health
Organization (WHO) has identified HTN as a global epidemic (WHO, 2013).
Cornerstone recommendations for the prevention, treatment and
management of HTN include a reduction in alcohol consumption, cessation of
tobacco smoking, maintenance of a healthy body weight, improvements in diet
and increases in physical exercise (e.g., aerobic exercise together with dynamic
resistance training), in addition to routine activities of daily living (Nerenberg et
al., 2018; Whelton et al., 2018). When lifestyle modifications alone do not
successfully control BP to within clinical target ranges (Eckel et al., 2014),
pharmacotherapy is used concomitantly (Owen et al., 2010; Leung et al., 2017;
Nerenberg et al., 2018; Whelton et al., 2018). Despite these intervention
strategies, less than 50% of those with HTN have their condition controlled to
target levels (Go et al., 2013). This may be attributable to many factors, such as
non-adherence to medication, diet and/or physical activity regimens, and the cost
of treatment (Brook et al., 2013; McGowan et al., 2017). Therefore, it is crucial to
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develop complementary and cost-effective strategies that can be used alone or in
conjunction with traditional BP-lowering interventions to better control BP (WHO,
2017).
Accordingly, alternative strategies have been investigated over the years
with varying degrees of success (e.g., meditation, biofeedback, device-guided
breathing), including isometric handgrip (IHG) training (Brook et al., 2013;
McGowan et al., 2017). After decades of accumulating proof-of-concept
evidence, the AHA/ACC now endorses IHG training as a treatment for HTN
management, citing it as a “Best Proven Nonpharmacological Interventions for
the Prevention and Treatment of Hypertension” in their most recent guidelines
(Brook et al., 2013; Whelton et al., 2018). Typically, an IHG protocol involves the
use of a computerized handgrip dynamometer with participants performing 4, 2minute sustained squeezes (isometric contractions), each separated by 1-minute
rest intervals (Badrov et al., 2013), at 30% of an individual’s maximum voluntary
contraction (MVC) performed 3-5 times per week for 8-10 weeks (Brook et al.,
2013; Millar et al., 2014; Inder et al., 2016; McGowan et al., 2017). However,
there is concern over the accessible and economic feasibility of using such
devices for widespread implementation.
The high cost of the computerized IHG dynamometer (> $600 CAD; Zona
Health, 2018) and lack of insurance coverage for the device creates an economic
barrier to its widespread uptake and implementation (Millar et al., 2008; Zhang et
al., 2014; McGowan et al., 2017; WHO, 2017). This notion of using an alternative
and affordable handgrip device has already been supported in the literature as
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an approach to elicit short-term training-induced reductions in BP for
normotensive older adults (Millar et al., 2008). Using a spring-loaded IHG device,
participants completed an 8 week, 3 times weekly, IHG training program, or were
part of a non-exercising control group. Participants randomized to the IHG group
trained at an intensity ranging from 15 to 30 pounds of force, depending on their
baseline maximum force or MVC. Pre-post reductions of 10 mmHg for systolic
BP and 3 mmHg for diastolic BP were observed with training, yet no change was
observed in the control group.
An alternative and even less expensive device than the spring-loaded
dynamometer previously investigated (Millar et al., 2008), one not reliant on
calibration equipment to regulate force, and one that can be performed by
individuals with mobility issues, balance issues, or barriers that may prevent
exercise involving lower extremities, is the widely known “stress ball”. Recent
work by Morrin et al., (2018) lay a foundation for designing effective IHG
protocols with alternative IHG devices. Using a pre-HTN and HTN cohort, it was
demonstrated that a rating of perceived exertion (CR-10; RPE) of 6 during a 2minute IHG contraction is equivalent to 30% MVC (Morrin et al., 2018). To date,
no study has investigated the acute (during a bout) or chronic (training) effects of
IHG on BP or other indices of cardiovascular and psychophysical function when
employed using a stress ball.
Before a long-term training investigation can be undertaken, it is important
to first examine and compare the acute stimuli of the inflatable stress ball with the
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computerized device, including cardiovascular (BP and heart rate, HR), and RPE
(similar to Morrin et al., 2018) responses.
2.2 Purposes and Hypotheses
The primary objective of the present investigation was to test the
hypothesis that an acute bout of IHG utilizing an inexpensive, readily available
inflatable stress ball would elicit a similar cardiovascular response (e.g.,
elevations in BP and HR) as the traditional computerized dynamometer device.
In addition, it was anticipated that an acute bout of IHG would elicit a similar RPE
of approximately 6 using both devices.
2.3 Clinical Significance
The current study extends the body of IHG training work and provides a
base for future training studies designed to investigate the effects of less
expensive devices on BP-reduction. The demonstration of similar cardiovascular
and RPE responses to a bout of IHG using a computerized device (Zona Health,
2018) and an inexpensive inflatable stress ball (approximately $4 CAD) suggests
that IHG training performed using the latter may have similar BP-lowering benefit.
Further, gaining a greater understanding of the subjective RPE will address a
gap exposed by Morrin et al. (2018) and generate knowledge that will inform
programing decisions as to the feasibility of device as a standard of care
treatment. Thus, this project lays the foundation for future studies to test efficacy
and outcome benefit, further promoting IHG as a treatment option for BP
management. Importantly, this work aligns with the WHO’s request for valid
prevention strategies that are equally cost-effective.
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2.4 Methods
2.4.1 Study Participants
Participants (healthy adults, ≥ 18 years old, resting BP <135/85 mmHg, no
overt disease, not taking prescription medication with the exception of birth
control pills, over the counter medications (e.g., Tylenol, Benedryl) from within
southwestern Ontario were recruited (Appendix A). All participants provided
written and informed consent (Appendix B), and all procedures were cleared by
the University of Windsor’s Research Ethics Board.
2.4.2 Study Design
Following consent and determination of eligibility, participants completed a
familiarization and testing session. Each of these sessions involved the
measurement of HR and BP while performing a bout of IHG on i) a computerized
IHG device (Zona Series 2, Zona Health, Boise, ID, USA, Appendix C) and, ii) a
store-bought inflatable ball (Part Number 020500, AllBall, Sportime, Thailand.
www.Amazon.com, Appendix D). The order of the two IHG methods
(computerized IHG device and inflatable ball) were randomized for each
participant with a 30-minute stabilization period between each bout. Total time to
complete the collective procedures was approximately 3 hours and included 2
points of contact.
Visit 1: Eligibility and Familiarization (approximately 1 hour)
Following informed consent, initially eligible participants completed the
Physical Activity and Readiness Questionnaire plus (PAR-Q+; Appendix E) and a
medical questionnaire (Appendix F) with the intent to screen for any ailments that

89

may exclude them from participating. Additionally, resting BP was measured after
10 minutes of seated rest to ensure inclusion BP criterion was met (<135/85
mmHg) according to standard protocol (Dinamap Carescape v100, Critikon 2333cm cuff, Tampa, Florida, USA; see Appendix G). Four measurements were
acquired, with 2-minute rest periods between each measurement, and the last 3
BP values averaged. Participants meeting all eligibility criteria proceeded to
protocol familiarization.
During the familiarization session, participants practiced the testing day
procedures. The session began with determination of maximal voluntary
contraction (MVC) on each device. The MVC for the computerized device (Series
2, Zona Health, Boise, ID, USA, see Appendix C) was automatically calculated
from internal linear load cells, using either the right or left hand (depending on
randomization). MVC for the inflatable stress ball (Part Number 020500, AllBall,
Sportime, Thailand. www.Amazon.com, see Appendix D) was calculated using a
digital air pressure gauge (Fox 40 International, 340 Grays Road, Hamilton,
Ontario, Canada, 2016, see Appendix H). Then respective 30% MVC were
calculated; for the computerized IHG device this calculation was done
automatically, and for the inflatable stress ball the following equation was used:
Equation 1: S= Max PSI x 0.30;
where S represents the 30% value, and Max PSI is the maximum air displaced;
the value displayed on the air gauge.
Once completed, the participant performed a 2-minute IHG bout at 30%
MVC using their right hand. After the bout was finished, the participant was given
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the chance to review the CR-10 scale (Appendix I) and have their BP measured
as per testing day procedures. After a 1-to-2-minute rest period, this process was
completed on the left hand and the alternative device was used for the second
bout to ensure minimal fatigue experienced during this familiarization session.
Visit 2: Testing Day (approximately 1.5 hours)
After confirmation of ongoing consent (Appendix B), and at least 24 hours
after the familiarization session, a single testing session occurred. All participants
were tested in the morning to control for the effects of circadian rhythm on BP,
and in a temperature-controlled room. Participants refrained from vigorous
physical activity over the previous 24 hours, were tested 2 hours postprandial
(i.e. 2 hours after eating) and at least 12 hours post-caffeine consumption. To
minimize the effects of a full bladder on BP, participants were asked to void his or
her bladder prior to testing.
Participants were seated for the duration of the testing period, with both their
right and left forearms resting on a table in front of them at an approximate 90degree angle. Participants were outfitted with the necessary equipment to assess
BP and HR (Dinamap Carescape v100, Critikon 23-33cm cuff, Tampa, Florida,
USA, see Appendix G). Resting BP was measured following 10 minutes of
seated rest as per the protocol described above. The protocols were separated
by a 30-minute rest period (minimum) or until the participant’s BP had returned to
near resting values.
In both conditions, the IHG bout consisted of 4, 2-minute bilateral (right and
left hand) contractions at 30% MVC each separated by a 1-minute rest period,
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where BP and HR are measured every minute and RPE was recorded after each
contraction (see Figure 1).
Figure 1: Testing Protocol

Note: Light blue line is the end of seated rest, each orange line is a blood pressure (BP) and
heart rate (HR) measurement completed with automated office blood pressure measurements
(AOBP) via Dinamap. Protocol began with a maximum voluntary contraction (MVC), where 30%
was calculated for both the Right (R) and Left (L) hands. After the participant engaged in 4, 2minute bilateral isometric handgrip (IHG) contractions, where a subjective rating of perceived
exertion (RPE) was recorded after each contraction. After, there is a 30-minute stabilization
period where BP and HR were measured. Once 30 minutes was complete the protocol began at
the yellow MVC square again with the second device.

2.4.3 Statistical Analysis
Two-way repeated measures ANCOVA (RMANCOVA) were used to
determine the effects of IHG device (independent variables: computerized or
inflatable stress ball) on BP (SBP, DBP), HR and CR-10 scores (dependent
variables). To determine specific differences between means, Boneferroni posthoc test(s) were employed where appropriate.
All data were analyzed using IBM SPSS Statistics 23 software (SPSS Inc.,
Chicago, Illinois, USA) and statistical significance was determined at p ≤ 0.05.
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Data is presented as mean and standard deviation (x̄ ± SD). Assumptions of
sphericity were met for all conditions, with the exception of DBP, where the
assumption for the two-way interaction between device and time was violated
(x2(2) = 11.31, p = 0.05). Thus, Greenhouse-Gieser was employed (€= 0.70).
2.5 Results
Twenty participants met the eligibility criteria and were enrolled in the
study (see Table 1), satisfying the minimum requirements for adequate power. All
participants completed visit 1 and visit 2, and adhered to pre-testing instructions.
Table 1: Participant Characteristics
Variable
Baseline Value
Men (#)
10
Women (#)
10
Age (years)
24.70 ± 5.13
Mass (kg)
74.16 ± 18.15
Height(cm)
171.67 ± 12.43
Resting SBP (mmHg)
107.93 ± 16.14
Resting DBP (mmHg)
58.68 ± 6.77
Resting HR (bpm)
66.01 ± 8.61
Note: SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.
Values are mean ± standard deviation (x̄ ± SD).

2.5.1 Comparison of Blood Pressure and Heart Rate
RMANCOVA revealed statistically significant BP and HR differences
between devices, whereby SBP and DBP were higher when the IHG protocol
was performed using the inflatable stress ball, yet there was a greater HR
response to the Zona-performed protocol (all p ≤ 0.05). Importantly, these
differences disappeared after review of pairwise comparison analyses (see Table
2 and Appendix J, K, L). The details of the analyses are as follows:
With respect to SBP, interaction effects for device and time (F (3,48) =
4.52, p = 0.007); device and order (F (1,16) = 5.06, p = 0.04); device, time and

93

order (F (3,48) = 2.84, p = 0.05); and device, time and fitness (F (3,48) = 3.14, p
= 0.03) were observed. As noted above, pairwise comparisons eliminated
statistically significant differences in SBP between devices (F (1,16) = 5.980, p =
0.615). Main effects were also observed for time (F (3,48) = 3.31, p=0.03), device
(F (1,16) = 5.98, p = 0.03), and sex (F (1,16) = 4.51, p = 0.05), yet pairwise
analyses revealed sex to be the only meaningful comparison in that men had a
significantly higher SBP response throughout the IHG protocols when compared
to women (x̄ ± SD (mmHg): 10.92 ± 1.13 for men and 7.40 ± 1.01 for women).
Between-subject differences for device, time, order, and fitness were not
observed.
Statistically significant differences in DBP were observed for both device
(F (1,16) = 5.111, p = 0.038), and time (F (3,48) = 3.285, p = 0.029). Like SBP,
pairwise comparison of each device denoted that although the inflatable stress
ball elicited a slightly higher DBP throughout the protocol, this was not
statistically significant (F (1,16) = 5.111, p = 0.35). However, unlike SBP, a main
effect of time was observed such that DBP was significantly higher in IHG
contraction 4 than it was during contraction 2 (CI 95%, 0.995 to 7.055, p =
0.006).
Regarding HR, statistically significant interactions were observed between
device and order of device (F (1,16) = 22.91, p = 0.00), as were main effects for
device (F (1,16) = 19.40, p = 0.00) and time (F (3,48) = 5.95, p = 0.00). In
contrast to BP, pairwise comparison of the devices revealed a higher HR
response when the IHG protocol was performed using the computerized device,
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yet like SBP and DBP, this difference was not statistically significant (F (1,16) =
19.40, p = 0.73). Further, the effect of order dissipated upon examination of
between-subjects effects (F (1,16) = 0.23, p = 0.64). No other meaningful
pairwise comparisons were revealed.
Overall, when the covariates of sex, device order, and fitness were
removed from the analysis, there were no statistically significant data to report
between devices.
Table 2: Cardiovascular Effects
Variable
Computerized Device
Inflatable Stress Ball
SBP (mmHg)
8.23 ± 9.47
9.10 ± 7.36
DBP (mmHg)
7.13 ± 7.77
8.86 ± 9.90
HR (bpm)
6.98 ± 7.50
6.53 ± 8.20
Note: SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate.
Values are mean ± standard deviation (x̄ ± SD).

2.5.2 Comparison of Subjective Rating of Perceived Exertion
Analysis by RMANCOVA indicated an interaction of time and sex (F (3,48)
= 2.83, p = 0.048) for RPE, and main effects for time (F (3,48) = 4.81, p = 0.005)
and fitness (F (1,16) = 5.062, p = 0.04). However, no main effects were observed
for sex, order and device regarding RPE. Although initially statistically significant
based on between-subjects interactions (F (1,16) = 5.062, p = 0.039), analysis of
pairwise comparisons revealed a lack of effect of fitness on RPE. Moreover,
pairwise comparison of devices indicated that the computerized device was
perceived to require greater effort by 0.337 (CI 95%, -0.27 to 0.94), but this result
was also not statistically significant (F (1,16) = 0.51, p = 0.26). In contrast,
pairwise comparison of contractions revealed some statistically significant
differences, but these differences were not meaningful (see Table 3).
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Table 3: Subjective Rating of Perceived Exertion
Scale

Device

RPE (1-10)

Computerized

RPE (1-10)

Inflatable
Stress Ball

Grand
Mean
+/- 5.76
1.83

Cont. 1

Cont. 2

Cont. 3

Cont. 4

+/- 5.25
1.80†‡

+/- 5.60
1.79†‡

+/- 6.05
1.93*+

+/- 6.15
1.79*+

+/- 5.42
1.78

+/- 5.10
1.59†‡

+/- 5.00
1.69†‡

+/- 5.70
1.78*+

+/- 5.90
2.02*+

Note: Rating of perceived exertion (RPE). Values are mean ± standard deviation (x̄ ±
SD).
*
Significant differences from contraction 1, +Significant differences from contraction 2,
†
Significant differences from contraction 3, ‡Significant differences from contraction 4.

2.6 Discussion
The long-term effects of IHG training on BP have been well documented
(Inder et al., 2016). However, widespread uptake and continued participation in
this form of exercise training has been hindered by the barrier of accessibility,
including cost, for the computerized device traditionally used. This study
illustrated that a cost-effective alternative can replicate acute HR and BP results
of more expensive and traditional IHG devices, laying a foundation for future
training studies.
Seminal work by Millar et al., (2008) comparing a less expensive,
alternative IHG device with the traditional, more expensive computerized model
found that following an 8 week training protocol there were statistically significant
decreases in both systolic and diastolic blood pressure (SBP and DBP). Although
the alternate IHG device was effective, there were numerous drawbacks, and the
notion of conducting research with other stand-alone, cost-effective devices
emerged (Millar et al., 2008; Inder et al., 2016; Whelton et al., 2018). The current
study adds to the literature as one of few studies examining the acute effects of
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an IHG bout on the cardiovascular system, and concomitant RPE. Furthermore, it
is the only known study to date to directly compare the traditional, costly
computerized device with a cost-effective option such as an inflatable stress ball.
Data from the current study was comparable to previous studies when
examining acute increases in BP during IHG exercise (Araujo et al., 2011; Olher
et al., 2013). As hypothesized, there were no statistical differences observed
between each device based on the examination of SBP, DBP, and HR. With no
significant differences between devices this introduces that IHG using inflatable
stress balls may facilitate a cost effective, widely available treatment opportunity
for lowering BP worldwide (WHO, 2013; WHO, 2017). Future studies need to
explore the long-term effect on BP adaptations with training.
Ratings of perceived exertion provide important insight into the potential
for IHG. The current study offers support for long-term feasibility in that both
devices elicit a similar engagement of perceived effort felt. Building on this
exciting potential was the observation that 30% MVC equated to an RPE of 5-6
for each contraction, a finding similar to work of Morrin et al., (2018). A prominent
limiting factor of the device investigated in the seminal work of Millar et al., (2008)
was that trained personnel were required to regulate the IHG training intensity.
Importantly, the current study provides insight into the ability of the participant to
self-regulate IHG exercise without the computerized device. The possibility that
an individual can use the inflatable stress ball, self-regulating 30% based on the
scale (approximately a 6), and without trained personnel, raises the feasibility
and effectiveness of the device.
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Overall, this work provides evidence that individual effort given to engage
in IHG exercise is the same for an inflatable stress ball as it was for the
computerized device. Moreover, these findings in combination with
implementation of the inflatable stress ball may allow a broader range of people
to participate in IHG exercise due to the affordability and comfortability of the
device, thereby addressing the call made by WHO (2017). Ultimately, this lays
the foundation to have a global impact on reducing BP through scaling up of IHG
training as a standard of care for the treatment of HTN with long-term adherence
to this form of exercise more likely.
2.7 Research Impact and Future Directions
The current study demonstrated similar cardiovascular (HR and BP
responses) and psychophysical (RPE) responses to a bout of IHG using a
traditional computerized device and an alternative inexpensive inflatable stress
ball. Thus, there are potential indications for promoting treatment compliance
over the long-term using the inflatable stress ball, while adding to the weight of
evidence recently provided by Morrin et al. (2018). These findings provide a
foundation for future studies to test efficacy and outcome benefit, further
promoting IHG as a treatment option for BP management.
Importantly, the current study is in alignment with the key health priorities
of the WHO, which emphasizes enhanced feasibility, low maintenance, and
inexpensive ways to effectively prevent, treat and manage HTN (WHO, 2017). In
addition to providing an alternative device for the treatment of HTN worldwide,
the current study and the potential implementation of the affordable inflatable
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stress ball provides support to meet these needs. These findings are of a
particular relevance to individuals residing in low to middle income countries
(LMIC) where HTN rates contribute to 75% of the global disease burden (WHO,
2017). This high prevalence rate is concomitant to poorer rates of HTN
awareness, treatment and control (Mills et al., 2015). Healthcare system-,
provider- and/or patient-level barriers, such as lack of access to care, high
provider burden, poor healthcare staffing, low patient health literacy, and lack of
treatment adherence, are also contributing factors (Mills et al., 2015; Musinguzi
et al., 2015). Taken together, implementation of cost effective, readily available
BP-lowering treatments that work, have a low provider burden, and offer a high
potential for uptake and long-term continuation are urgently needed in LMICs.
The potential to offer IHG training using an inflatable stress ball as a BP-lowering
standard of care treatment in primary care is timely and enticing.
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Appendices
Appendix A: Recruitment Poster, Email Script, Presentation Script

Do you think you have normal blood
pressure?

If so, you may be eligible to participate in a study examining the effects of
handgrip exercise on blood pressure.
If you are interested and would like more information please call: (519) -2533000
ext. 4979 or email: richardu@uwindsor.ca
Jared
Richards:
richardu@
uwindsor.
ca
519-2533000 ext.
4979

Jared
Richards:
richardu@
uwindsor.
ca
519-2533000 ext.
4979

Jared
Richards:
richardu@
uwindsor.
ca
519-2533000 ext.
4979

Jared
Richards:
richardu@
uwindsor.
ca
519-2533000 ext.
4979

Jared
Richards:
richardu@
uwindsor.
ca
519-2533000 ext.
4979

Jared
Richards:
richardu@
uwindsor.
ca
519-2533000 ext.
4979

Jared
Richards:
richardu@
uwindsor.
ca
519-2533000 ext.
4979

This study has been cleared by the University of Windsor’s Research Ethics Board
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Jared
Richard
richard
uwinds
ca
519-253
3000 ex
4979

Email to be sent by Sharon Horne, the Human Kinetics Administrative Assistant
to Department Head and Graduate Program Secretary and Undergraduate
Program Secretary after receiving the email from Mr. Richards along with a
request to forward it to all Human Kinetics Students:

"Attention all people over the age of 18 years. If you think you have normal blood
pressure, you may be eligible to participate in a research study being conducted
by researchers in the Department of Kinesiology at the University of Windsor.
We are investigating the effects of isometric (constant squeeze) handgrip
exercise on your blood pressure and heart rate. For more information please
contact Jared at 519-253-3000 ex. 4979 or richardu@uwindsor.ca”

Presentation to be delivered by Mr. Richards when speaking to a group of
individuals from research laboratories, undergraduate classes and/or community
exercise facilities
“Hello everyone, my name is Jared Richards, and I am a Master’s Student at the
University of Windsor conducting research in the Department of Kinesiology. My
colleagues and I are investigating the effects of isometric, or constant squeeze,
handgrip exercise on blood pressure and heart rate. We are looking to compare
expensive computerized devices and cheaper alternatives, like stress balls, to
see if they are different. If you are over the age of 18 and think you have normal
blood pressure than you may be eligible to participate. Feel free to contact me by
phone at 519-253-3000 ex. 4979 or by emailing me at richardu@uwindsor.ca.
Thank you for your time.
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Appendix B: Letter of Consent and Letter of Information
Note: Each of these are found on the pages following.
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CONSENT TO PARTICIPATE IN RESEARCH
Title of Study: Getting the Best GRIP on Blood Pressure Control: Are
Stress Balls and Handgrips Equally Effective?
You are invited to participate in a research study conducted by Mr. Jared Richards from
the Faculty of Human Kinetics at the University of Windsor.
If you have any questions or concerns about the research, please feel to contact
co-investigators Mr. Jared Richards BHK, MHK Candidate (richardu@uwindsor.ca),
Dr. Cheri McGowan, PhD (mcgowanc@uwindsor.ca) and Dr. Paula van Wyk, PhD
(pvanwyk@uwindsor.ca)

PURPOSE OF THE STUDY
Our research group and others have shown that isometric (constant squeeze) exercise
training using a computerized isometric handgrip device (isometric handgrip, IHG) lowers
resting blood pressure (BP) in younger and older people, and in those with and without
high BP. Currently, computerized IHG is very expensive, therefore, it is important to
determine if a store purchased inexpensive inflatable ball (similar to a stress ball) does
something similar. The purpose of this study is to investigate if the two devices of differing
costs cause similar body cardiovascular responses (e.g. BP and heart rate).
In order to participate in this study, you must have a normal BP (<135/85 mmHg), and
you must be over 18 years old. If you have a disorder, or any known ailments, are a
chronic smoker (nicotine, vaping, and/or marijuana), or are taking any medications that
influence your cardiovascular system (other than the birth control pill) you may be
ineligible to participate. If you have a physical limitation impairing your ability to exercise
you may also be ineligible to participate.

PROCEDURES
If you volunteer to participate in this study, you will be invited to attend two lab sessions:
First Visit: Familiarization and Information Session (1 Hour)
You will meet with the study investigators at the Physical Activity and Cardiovascular
Research (PACR) Laboratory (Room #240, Human Kinetics Building, University of
Windsor, Windsor, Ontario, Canada) where you will receive a consent form and
information sheet about the study. At this time, one of the study investigators will explain
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all parts of the study. If you are still interested in participating in the study, you will sign
the consent form and fill out two brief medical questionnaires. If you are still eligible to
participate, you will then have your BP measured in your upper right arm, similar to how
it is taken at a doctor’s office. In brief, your resting BP will be measured in your upper right
arm after 10 minutes of seated rest. Your BP will be measured 4 times, with 2 minutes of
rest between measures. If you are still eligible to participate, you will then have an
opportunity to practice all parts of the study.
Second Visit: Testing Day (1.5 Hours)
If you are still interested in participating in the study, you will visit the lab at least 24 hours
following first visit.
In order to participate on the testing day ongoing consent will be needed. It is also
important that you refrain from participation in strenuous exercise (e.g., difficult, high
intensity exercise that causes heavy breathing, sweating, and muscle fatigue) for 24
hours before the testing day, and to avoid caffeine, consumption of alcohol, and over the
counter medication for at least 12 hours before. All testing will be scheduled to take place
2 hours after your last meal, in a quiet, temperature-controlled room in the presence of
the study investigators. You will be asked to go to the washroom prior to testing, as a full
bladder can increase BP.
For the duration of the test, you will be asked to remain seated with your arms at a 90degree angle placed on a table in front of you. You will be outfitted with a blood
pressure cuff around your right arm to take BP and heart rate (HR) measurements.
These measures will be collected continuously for 10 minutes prior to, during, and for at
least 30 minutes following each isometric handgrip (IHG) bout. Next, you will be given
10 minutes of seated rest. Following the rest period, BP measurements will be taken in
order to establish your baseline measurements. Following these measurements, your
maximum voluntary contraction (MVC; hardest squeeze) will be calculated using each
handgrip (traditional, computerized IHG and the inflatable ball) in order to determine the
intensity to which the IHG bouts will be performed.
Next, you will be asked perform, in random order, an IHG protocol on the computerized
IHG device and the store-bought inflatable ball. The protocols will be separated by a 30minute rest period (minimum) or until your BP has returned to near resting values. In both
conditions, the IHG bout will consist of 4, 2-minute bilateral (right and left) contractions
at 30% of the MVC, each separated by 4-minute rest period. Following each 2-minute
contraction, you will be asked to rate your level of perceived exertion using a 1-10 scale.
Upon completion of the final bout of handgrip, there will a final stabilization period to
ensure that your BP returns to near pre-exercise values.

POTENTIAL RISKS AND DISCOMFORTS
During the study, it is possible you may experience tingling in the upper arm due to the
inflation of the blood pressure cuff, but this should subside when the cuff deflates. Muscle
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fatigue in the hand may occur in the hand during the protocols due to the IHG bouts.
However, because this is an acute single session study, proper technique and instruction
will be given to participants, which results in minimal risk.
Please contact one of the study investigators if you feel any adverse effects from
completing any portion of the study, and/or if you have any questions or concerns. If
you experience any adverse effects during any testing procedure, first line response will
be provided.

POTENTIAL BENEFITS TO PARTICIPANTS AND/OR TO SOCIETY
You may not experience any direct benefit by participating in this single session study,
however you will learn how your heart rate and blood pressure changes during a bout of
handgrip exercise. However, if we prove our theories, evidence of the equivalence of an
inflatable ball in comparison to the traditional, more expensive computerized IHG may lay
the groundwork for future studies investigating the use of affordable, commercially
available handgrips as a means to lower BP.

COMPENSATION FOR PARTICIPATION
All participants will receive a Kinesiology Research item (e.g., T-shirt) of their choice upon
completion of the study.

CONFIDENTIALITY
Any information that is obtained in connection with this study that can identify you will
remain confidential.
To ensure your confidentiality, following your consent, you will be assigned a study code.
Your name will not be mentioned in any publication or presentation, and you will be
identified with only your study code on all collection tools (electronic or otherwise). All
paper data will be stored in the locked laboratory (PACR Lab, Room #240, Human
Kinetics Building, University of Windsor). Information stored on computer will be
password-accessible only. With respect to final disposal, all paper records (including
medical and physical activity readiness questionnaires) will be shredded after 5 years.

PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not, and your participation or lack of it will
not influence your participation in another study. If you volunteer to be in this study, you
may withdraw at any time prior to July 25th without consequences of any kind. The
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investigator may withdraw you from this research if circumstances arise which warrant
doing so. In any of the cases described above, you will still receive a Kinesiology research
item of your choice.

FEEDBACK OF THE RESULTS OF THIS STUDY TO THE
PARTICIPANTS
Results will be posted at the completion of the study on approximately August 25th under
the University of Windsor’s Research Ethics Board (REB) website at:
http://www.uwindsor.ca/reb

SUBSEQUENT USE OF DATA
These data may be used in subsequent studies, in publications and in presentations.
However, your privacy will be upheld with the use of your unique subject study code
under all circumstances. Data may be used as a foundation for future study of storebought, readily available IHG, and/or merged with other data sets for comparison.

RIGHTS OF RESEARCH PARTICIPANTS
If you have questions regarding your rights as a research participant, contact: Research
Ethics Coordinator, University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519253-3000, ext. 3948; e-mail: ethics@uwindsor.ca

SIGNATURE OF RESEARCH PARTICIPANT/LEGAL
REPRESENTATIVE
I understand the information provided for the study: Getting the Best GRIP on Blood
Pressure Control: Are Stress Balls and Handgrips Equally Effective? Response as
described herein. My questions have been answered to my satisfaction, and I agree to
participate in this study. I have been given a copy of this form.
______________________________________
Name of Participant
______________________________________
___________________
Date

Signature of Participant
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SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.
_____________________________________
____________________
Date

Signature of Investigator

Second Visit (Ongoing Consent):
I understand the information provided for the study: Getting the Best GRIP on Blood
Pressure Control: Are Stress Balls and Handgrips Equally Effective? described herein.
My questions have been answered to my satisfaction, and I agree to participate in this
study. I consent (agree) to continue being a participant in this study.
______________________________________
Name of Participant
______________________________________
___________________
Date

Signature of Participant
_____________________________________

____________________
Date

Signature of Investigator
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LETTER OF INFORMATION FOR CONSENT TO PARTICIPATE IN
RESEARCH
Title of Study: Getting the Best GRIP on Blood Pressure Control: Are
Stress Balls and Handgrips Equally Effective?
You are invited to participate in a research study conducted by Mr. Jared Richards from
the Faculty of Human Kinetics at the University of Windsor.
If you have any questions or concerns about the research, please feel to contact
co-investigators Mr. Jared Richards (richardu@uwindsor.ca), Dr. Cheri McGowan,
PhD
(mcgowanc@uwindsor.ca)
and
Dr.
Paula
van
Wyk,
PhD
(pvanwyk@uwindsor.ca)

PURPOSE OF THE STUDY
Our research group has shown that isometric (constant squeeze) exercise training using
a computerized isometric handgrip device (isometric handgrip, IHG) lowers resting blood
pressure (BP) in younger and older people, and in those with and without high BP.
Currently, computerized IHG is very expensive, therefore, it is important to determine if
a store purchased inexpensive inflatable ball (similar to a stress ball) has similar results
to the more expensive devices. The purpose of this study is to investigate if the two
devices of differing costs cause similar body cardiovascular responses (e.g. BP rates).
In order to participate in this study, you must have a normal BP (<135/85 mmHg), and
you must be over 18 years old. If you have a disorder or any known ailments, are a chronic
smoker (nicotine, vaping, and/or marijuana), or are taking any medications that influence
your cardiovascular system (other than the birth control pill) you may be ineligible to
participate. If you have a physical limitation impairing your ability to exercise you may also
be ineligible to participate.

PROCEDURES
If you volunteer to participate in this study, you will be invited to:
First Visit: Familiarization and Information Session (1 Hour)
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You will meet with the study investigators at the Physical Activity and Cardiovascular
Research (PACR) Laboratory (Room #240, Human Kinetics Building, University of
Windsor, Windsor, Ontario, Canada) where you will receive a consent form and
information sheet about the study. At this time, one of the study investigators will explain
all parts of the study. If you are still interested in participating in the study, you will sign
the consent form and fill out brief medical questionnaires. If you are still eligible to
participate, you will then have your BP measured in your upper arm, similar to how it is
taken at a doctor’s office. In brief, your resting BP will be measured in your upper right
arm after 10 minutes of seated rest. Your BP will be measured 4 times, with 2 minutes of
rest between measures. If you are eligible to participate, you will then have an opportunity
to practice all parts of the study.
Second Visit: Testing Day (1.5 Hours)
If you are still interested in participating in the study, you will visit the lab at least 24 hours
following first visit.
In order to participate on the testing day ongoing consent will be needed. It is also it
important that you refrain from participation in strenuous exercise (e.g., difficult, high
intensity exercise that causes heavy breathing, sweating, and muscle fatigue) for 24
hours before the testing day, and to avoid caffeine, consumption of alcohol, and over the
counter medication for at least 12 hours before. All testing will be scheduled to take place
2 hours after your last meal, in a quiet, temperature-controlled room in the presence of
the study investigators. You will be asked to go to the washroom prior to testing, as a full
bladder can increase BP.
For the duration of the test, you will be asked to remain seated with your arms at a 90degree angle placed on a table in front of you. You will be outfitted with a blood
pressure cuff around your right arm to take BP and heart rate (HR) measurements.
These measures will be collected continuously for 10 minutes prior to, during, and for at
least 30 minutes following each isometric handgrip (IHG) bout. Next, you will be given
10 minutes of seated rest. Following the rest period, BP measurements will be taken in
order to establish your baseline measurements. Following these measurements, your
maximum voluntary contraction (MVC; hardest squeeze) will be calculated using each
handgrip (traditional, computerized IHG and the inflatable ball) in order to determine the
intensity to which the IHG bouts will be performed.
Next, you will be asked perform, in random order, an IHG protocol on the computerized
IHG device and the store-bought inflatable ball. The protocols will be separated by a 30minute rest period (minimum) or until your BP has returned to near resting values. In both
conditions, the IHG bout will consist of 4, 2-minute bilateral (right and left) contractions
at 30% of the MVC, each separated by 4-minute rest period. Following each 2-minute
contraction, you will be asked to rate your level of perceived exertion using a 1-10 scale.
Upon completion of the final bout of handgrip, there will a final stabilization period to
ensure that your BP returns to near pre-exercise values.
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POTENTIAL RISKS AND DISCOMFORTS
During the study, it is possible you may experience tingling in the upper arm due to the
inflation of the blood pressure cuff, but this should subside when the cuff deflates. Muscle
fatigue in the hand may occur in the hand during the protocols due to the IHG bouts.
However, because this is an acute single session study, proper technique and instruction
will be given to participants, which results in minimal risk.
Please contact one of the study investigators if you feel any adverse effects from
completing any portion of the study, and/or if you have any questions or concerns. If
you experience any adverse effects during any testing procedure, first line response will
be provided.

POTENTIAL BENEFITS TO PARTICIPANTS AND/OR TO SOCIETY
You may not experience any physical direct benefit by participating in this single session
study. However, if we prove our theories, evidence of the equivalence of an inflatable ball
in comparison to the traditional, more expensive computerized IHG may lay the
groundwork for future studies investigating the use of affordable, commercially available
handgrips as a means to lower BP.

COMPENSATION FOR PARTICIPATION
All participants will receive a Kinesiology Research item of their choice (e.g. shirt) upon
completion of the study.

CONFIDENTIALITY
Any information that is obtained in connection with this study that can identify you will
remain confidential.
To ensure your confidentiality, following your consent, you will be assigned a study code.
Your name will not be mentioned in any publication or presentation, and you will be
identified with only your study code on all collection tools (electronic or otherwise). All
paper data will be stored in the locked laboratory (PACR Lab, Room #240, Human
Kinetics Building, University of Windsor). Information stored on computer will be
password-accessible only. With respect to final disposal, all paper records (including
medical and physical activity readiness questionnaires) will be shredded after 5 years.
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PARTICIPATION AND WITHDRAWAL
You can choose whether to be in this study or not, and your participation or lack of it will
not influence your participation in another study. If you volunteer to be in this study, you
may withdraw at any time prior to July 25th without consequences of any kind. The
investigator may withdraw you from this research if circumstances arise which warrant
doing so. In any of the cases described above, you will still receive a Kinesiology
Research item of your choice.

FEEDBACK OF THE RESULTS OF THIS STUDY TO THE
PARTICIPANTS
Results will be posted at the completion of the study on approximately August 25th under
the University of Windsor’s Research Ethics Board (REB) website at:
http://www.uwindsor.ca/reb

SUBSEQUENT USE OF DATA
These data may be used in subsequent studies, in publications and in presentations
however your privacy will be upheld with the use of your unique subject study code under
all circumstances. Data may be used as a foundation for future study of store-bought,
readily available IHG, and/or merged with other data sets for comparison.

RIGHTS OF RESEARCH PARTICIPANTS
If you have questions regarding your rights as a research participant, contact: Research
Ethics Coordinator, University of Windsor, Windsor, Ontario, N9B 3P4; Telephone: 519253-3000, ext. 3948; e-mail: ethics@uwindsor.ca

SIGNATURE OF INVESTIGATOR
These are the terms under which I will conduct research.
_____________________________________
____________________
Signature of Investigator

Date
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Appendix C: Computerized IHG Device

a) Top view

b) Side view to show the area for the hand grip
Computerized Isometric Handgrip tool, Zona (Zona Series 3, Zona Health, Boise, ID,
USA)
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Appendix D: Inflatable Stress Ball

Inflatable Stress Ball (Part Number 020500, AllBall, Sportime, Thailand.
www.Amazon.com)
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Appendix E: Physical Activity Readiness Questionnaire Plus (PAR-Q +)

120

121

122

123

Appendix F: Intake Medical Questionnaire
Participant Code: ________________
Mass: _________________________

Date of Birth (MM/YYYY): _________________ Height: __________________
Phone: (___)
Postal Code:
__________________
_______________________

FOR EMERGENCY
Notify:
Relationship:
Address:_____________________________________________________________________
Phone: (___) _______________
Family Doctor’s Name: ______________________ Date of Last Physical: ______________________
Please Check YES or NO for each of the following:
1. Have you ever been hospitalized?...........................................................................................................
- If YES, please specify:
Have you ever had surgery?.........................................................................................................................
- If YES, please specify:
2. Are you presently taking any medications or pills (including aspirin and other over-the-counter
medications?................................................................................................................................................
- If YES, please specify:
Are you presently taking any vitamins, supplements, and/or herbal supplements?...................................
3. Do you have any allergies (medicine, food, bees or other stinging insects)?..........................................
- If YES, please specify:
4. Have you ever passed out during or after exercise?................................................................................
Have you ever been dizzy during or after exercise?....................................................................................
Have you ever had chest pain during or after exercise?..............................................................................
Do you have high blood pressure (hypertension) or low blood pressure (hypotension)?..........................
Have you ever been told that you have a kidney problem?........................................................................
Have you ever been told that you have joint instability?............................................................................
Have you ever been told that you have a stomach problem?.....................................................................
Have you ever been told that you have a heart problem?..........................................................................
Have you ever been told that you have a heart murmur?...........................................................................
Do you have a machine that regulated your heart beat?............................................................................
Have you ever had racing of your heart or skipped heartbeats?.................................................................
Has anyone in your family died of heart problems or a sudden death before age 50 years?.....................
5. Do you have any skin problems (itching, rashes, acne)?..........................................................................
If you get a cut, does it take you a long time to stop bleeding?..................................................................
If you experience a blow to a muscle, do you bruise easily?.......................................................................
6. Do you have Diabetes?.............................................................................................................................
7. Do you have Asthma or any other breathing problems?.........................................................................
- If YES, please specify:
8. Do you have any type of cardiovascular disease?....................................................................................
- If YES, please specify:
9. Have you had any other medical problems (infectious mononucleosis, etc.)?........................................
10. Have you had any medical problems since your last physical?..............................................................
11. Do you smoke?.......................................................................................................................................
12. Do you aerobically exercise (e.g. walking) for > 30 minutes, > 2 times per week?................................
13. Do you currently take any birth control medications?...........................................................................
- If YES, please specify:
14. Date of last menstrual cycle:
Please explain any physical limitations that may prevent you from completing this study?
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YES

NO

Appendix G: Automated Oscillometry Device / DINAMAP

(Dinamap Carescape v100, Critikon 23-33 cm cuff, Tampa, Florida, USA)
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Appendix H: Digital Air Pressure Gauge

Used to determine MVC with the inflatable ball
Digital Ball Gauge (Fox 40 International, 340 Grays Road, Hamilton, Ontario, Canada,
2016)
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Appendix I: Borg CR-10 Scale (RPE)
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Appendix J: Systolic Blood Pressure Results

Mauchly's Test of Sphericitya
Measure: MEASURE_1
Within Subjects Effect
Device
Time
Device * Time

Mauchly's W
1.000
.494
.586

Approx. ChiSquare
.000
10.371
7.859

df

Sig.
0
5
5

.
.066
.165

Epsilonb
GreenhouseGeisser
1.000
.752
.747

Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
Device

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * SEX
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * Option Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * Fitness Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Error(Device)
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

Time

Type III
Sum of
Squares
697.925

Partial
Noncent.
Eta
Paramete Observed
Squared
r
Powera
.272
5.980
.632

1

Mean
Square
697.925

F
5.980

Sig.
.026

697.925

1.000

697.925

5.980

.026

.272

5.980

.632

697.925
697.925
10.361

1.000
1.000
1

697.925
697.925
10.361

5.980
5.980
.089

.026
.026
.770

.272
.272
.006

5.980
5.980
.089

.632
.632
.059

10.361

1.000

10.361

.089

.770

.006

.089

.059

10.361
10.361
590.340

1.000
1.000
1

10.361
10.361
590.340

.089
.089
5.058

.770
.770
.039

.006
.006
.240

.089
.089
5.058

.059
.059
.561

590.340

1.000

590.340

5.058

.039

.240

5.058

.561

590.340
590.340
295.696

1.000
1.000
1

590.340
590.340
295.696

5.058
5.058
2.534

.039
.039
.131

.240
.240
.137

5.058
5.058
2.534

.561
.561
.322

295.696

1.000

295.696

2.534

.131

.137

2.534

.322

295.696
295.696
1867.354

1.000
1.000
16

295.696
295.696
116.710

2.534
2.534

.131
.131

.137
.137

2.534
2.534

.322
.322

1867.354

116.710

150.717

3.310

.028

.171

9.930

.719

df

Lower-bound

1867.354

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound

452.150

16.00
0
16.00
0
16.00
0
3

452.150

2.255

200.542

3.310

.043

.171

7.463

.624

452.150
452.150

3.000
1.000

150.717
452.150

3.310
3.310

.028
.088

.171
.171

9.930
3.310

.719
.402

1867.354

116.710
116.710

128

Time * SEX

Time * Option

Time * Fitness

Error(Time)

Device * Time

Device * Time *
SEX

Device * Time *
Option

Device * Time *
Fitness

Error(Device*Ti
me)

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

264.266

3

88.089

1.935

.137

.108

5.804

.468

264.266

2.255

117.210

1.935

.155

.108

4.362

.397

264.266
264.266
83.673

3.000
1.000
3

88.089
264.266
27.891

1.935
1.935
.613

.137
.183
.610

.108
.108
.037

5.804
1.935
1.838

.468
.258
.168

83.673

2.255

37.112

.613

.566

.037

1.381

.150

83.673
83.673
139.985

3.000
1.000
3

27.891
83.673
46.662

.613
.613
1.025

.610
.445
.390

.037
.037
.060

1.838
.613
3.074

.168
.114
.261

139.985

2.255

62.088

1.025

.377

.060

2.310

.226

139.985
139.985
2185.615

3.000
1.000
48

46.662
139.985
45.534

1.025
1.025

.390
.326

.060
.060

3.074
1.025

.261
.159

2185.615

60.587

195.684

4.515

.007

.220

13.545

.856

Lower-bound

2185.615

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

587.052

36.07
4
48.00
0
16.00
0
3

587.052

2.241

262.004

4.515

.015

.220

10.116

.767

587.052
587.052
278.175

3.000
1.000
3

195.684
587.052
92.725

4.515
4.515
2.139

.007
.050
.108

.220
.220
.118

13.545
4.515
6.418

.856
.515
.512

278.175

2.241

124.151

2.139

.127

.118

4.794

.433

278.175
278.175
369.855

3.000
1.000
3

92.725
278.175
123.285

2.139
2.139
2.844

.108
.163
.047

.118
.118
.151

6.418
2.139
8.533

.512
.280
.646

369.855

2.241

165.068

2.844

.066

.151

6.373

.552

369.855
369.855
408.790

3.000
1.000
3

123.285
369.855
136.263

2.844
2.844
3.144

.047
.111
.034

.151
.151
.164

8.533
2.844
9.432

.646
.354
.695

408.790

2.241

182.445

3.144

.050

.164

7.044

.598

408.790
408.790
2080.410

3.000
1.000
48

136.263
408.790
43.342

3.144
3.144

.034
.095

.164
.164

9.432
3.144

.695
.385

2080.410

35.85
0
48.00
0
16.00
0

58.031

Lower-bound

2185.615

2080.410
2080.410

45.534
136.601

43.342
130.026
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a. Computed using alpha = .05

Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
Intercept
856.767
SEX
345.676
Option
54.038
Fitness
151.336
Error
1226.814

df

Mean Square
856.767
345.676
54.038
151.336
76.676

1
1
1
1
16

F
11.174
4.508
.705
1.974

Sig.
.004
.050
.414
.179

Partial Eta
Squared
.411
.220
.042
.110

Pairwise Comparisons
Measure: MEASURE_1
(I) Device
1
2

(J) Device
2
1

Mean Difference
(I-J)
-.875
.875

Sig.a
.615
.615

Std. Error
1.708
1.708

95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-4.496
2.746
-2.746
4.496

Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.

Pairwise Comparisons
Measure: MEASURE_1
(I) Time
1

2

3

4

(J) Time
2
3
4
1
3
4
1
2
4
1
2
3

Mean Difference
(I-J)
-1.975
-1.550
-5.125
1.975
.425
-3.150
1.550
-.425
-3.575
5.125
3.150
3.575

Std. Error
1.434
.908
1.796
1.434
1.602
1.514
.908
1.602
1.642
1.796
1.514
1.642

Sig.a
1.000
.642
.069
1.000
1.000
.324
.642
1.000
.268
.069
.324
.268

Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.
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95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-6.288
2.338
-4.280
1.180
-10.528
.278
-2.338
6.288
-4.395
5.245
-7.705
1.405
-1.180
4.280
-5.245
4.395
-8.514
1.364
-.278
10.528
-1.405
7.705
-1.364
8.514

Appendix K: Diastolic Blood Pressure Results
Mauchly's Test of Sphericitya
Measure: MEASURE_1
Within Subjects Effect
Device
Time
Device * Time

Mauchly's W
1.000
.652
.464

Approx. ChiSquare
.000
6.305
11.310

df

Sig.
0
5
5

.
.279
.046

Epsilonb
GreenhouseGeisser
1.000
.776
.702

Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
Device

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * SEX
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * Option Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * Fitness Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Error(Device)
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

Time

Time * SEX

Type III
Sum of
Squares
655.809

Partial
Noncent.
Eta
Paramete Observed
Squared
r
Powera
.242
5.111
.565

1

Mean
Square
655.809

F
5.111

Sig.
.038

655.809

1.000

655.809

5.111

.038

.242

5.111

.565

655.809
655.809
329.576

1.000
1.000
1

655.809
655.809
329.576

5.111
5.111
2.569

.038
.038
.129

.242
.242
.138

5.111
5.111
2.569

.565
.565
.326

329.576

1.000

329.576

2.569

.129

.138

2.569

.326

329.576
329.576
330.025

1.000
1.000
1

329.576
329.576
330.025

2.569
2.569
2.572

.129
.129
.128

.138
.138
.138

2.569
2.569
2.572

.326
.326
.326

330.025

1.000

330.025

2.572

.128

.138

2.572

.326

330.025
330.025
20.553

1.000
1.000
1

330.025
330.025
20.553

2.572
2.572
.160

.128
.128
.694

.138
.138
.010

2.572
2.572
.160

.326
.326
.066

20.553

1.000

20.553

.160

.694

.010

.160

.066

20.553
20.553
2052.853

1.000
1.000
16

20.553
20.553
128.303

.160
.160

.694
.694

.010
.010

.160
.160

.066
.066

2052.853

128.303

85.934

3.285

.029

.170

9.856

.716

df

Lower-bound

2052.853

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser

257.801

16.00
0
16.00
0
16.00
0
3

257.801

2.327

110.796

3.285

.042

.170

7.645

.631

257.801
257.801
62.676

3.000
1.000
3

85.934
257.801
20.892

3.285
3.285
.799

.029
.089
.501

.170
.170
.048

9.856
3.285
2.396

.716
.399
.209

62.676

2.327

26.936

.799

.474

.048

1.859

.186

2052.853

128.303
128.303
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Time * Option

Time * Fitness

Error(Time)

Device * Time

Device * Time *
SEX

Device * Time *
Option

Device * Time *
Fitness

Error(Device*Ti
me)

Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

62.676
62.676
76.969

3.000
1.000
3

20.892
62.676
25.656

.799
.799
.981

.501
.385
.410

.048
.048
.058

2.396
.799
2.943

.209
.134
.251

76.969

2.327

33.079

.981

.395

.058

2.282

.221

76.969
76.969
210.588

3.000
1.000
3

25.656
76.969
70.196

.981
.981
2.684

.410
.337
.057

.058
.058
.144

2.943
.981
8.051

.251
.154
.618

210.588

2.327

90.505

2.684

.074

.144

6.245

.538

210.588
210.588
1255.481

3.000
1.000
48

70.196
210.588
26.156

2.684
2.684

.057
.121

.144
.144

8.051
2.684

.618
.338

1255.481

33.723

42.144

1.475

.233

.084

4.425

.365

Lower-bound

1255.481

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

126.433

37.22
9
48.00
0
16.00
0
3

126.433

2.106

60.037

1.475

.243

.084

3.106

.300

126.433
126.433
12.295

2.887
1.000
3

43.788
126.433
4.098

1.475
1.475
.143

.235
.242
.933

.084
.084
.009

4.259
1.475
.430

.357
.208
.074

12.295

2.106

5.839

.143

.877

.009

.302

.071

12.295
12.295
116.847

2.887
1.000
3

4.258
12.295
38.949

.143
.143
1.363

.928
.710
.265

.009
.009
.079

.414
.143
4.089

.074
.065
.340

116.847

2.106

55.486

1.363

.270

.079

2.871

.279

116.847
116.847
49.701

2.887
1.000
3

40.468
116.847
16.567

1.363
1.363
.580

.266
.260
.631

.079
.079
.035

3.936
1.363
1.739

.332
.196
.161

49.701

2.106

23.601

.580

.574

.035

1.221

.140

49.701
49.701
1371.518

2.887
1.000
48

17.213
49.701
28.573

.580
.580

.625
.457

.035
.035

1.674
.580

.159
.111

1371.518

33.69
4
46.19
9
16.00
0

40.705

Lower-bound

1255.481

1371.518
1371.518

26.156
78.468

29.687
85.720

a. Computed using alpha = .05
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Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
Intercept
901.207
SEX
130.007
Option
2.239
Fitness
79.651
Error
5861.906

df

Mean Square
901.207
130.007
2.239
79.651
366.369

1
1
1
1
16

F
2.460
.355
.006
.217

Sig.
.136
.560
.939
.647

Partial Eta
Squared
.133
.022
.000
.013

Pairwise Comparisons
Measure: MEASURE_1
(I) Device
1
2

(J) Device
2
1

Mean Difference
(I-J)
-1.738
1.738

Sig.a
.346
.346

Std. Error
1.791
1.791

95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-5.534
2.059
-2.059
5.534

Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.

Pairwise Comparisons
Measure: MEASURE_1
(I) Time
1

2

3

4

(J) Time
2
3
4
1
3
4
1
2
4
1
2
3

Mean Difference
(I-J)
1.200
-1.550
-2.825
-1.200
-2.750
-4.025*
1.550
2.750
-1.275
2.825
4.025*
1.275

Std. Error
1.011
1.013
1.472
1.011
1.004
1.007
1.013
1.004
1.268
1.472
1.007
1.268

Sig.b
1.000
.874
.438
1.000
.088
.006
.874
.088
1.000
.438
.006
1.000

Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
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95% Confidence Interval for
Differenceb
Lower Bound
Upper Bound
-1.842
4.242
-4.598
1.498
-7.253
1.603
-4.242
1.842
-5.771
.271
-7.055
-.995
-1.498
4.598
-.271
5.771
-5.089
2.539
-1.603
7.253
.995
7.055
-2.539
5.089

Appendix L: Heart Rate Results
Mauchly's Test of Sphericitya
Measure: MEASURE_1
Within Subjects Effect
Device
Time
Device * Time

Mauchly's W
1.000
.655
.855

Approx. ChiSquare
.000
6.230
2.299

df

Sig.
0
5
5

.
.285
.807

Epsilonb
GreenhouseGeisser
1.000
.833
.901

Tests of Within-Subjects Effects
Measure: MEASURE_1
Type III
Sum of
Squares
1299.683

Mean
df
Square
1 1299.683

1299.683

1.000 1299.683

1299.683

1.000 1299.683

Lower-bound

1299.683

1.000 1299.683

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * Option Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

124.112

1

124.112

1.000

Source
Device

Sig.
.000

124.112

F
19.40
2
19.40
2
19.40
2
19.40
2
1.853

124.112

124.112
124.112
1534.601

1.000 124.112
1.000 124.112
1 1534.601

1534.601

1.000 1534.601

1534.601

1.000 1534.601

Lower-bound

1534.601

1.000 1534.601

Device * Fitness Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Error(Device)
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

186.122

1

186.122

Lower-bound

1071.778

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

Device * SEX

Time

Partial
Noncent.
Eta
Paramete Observed
Squared
r
Powera
.548
19.402
.985

.000

.548

19.402

.985

.000

.548

19.402

.985

.000

.548

19.402

.985

.192

.104

1.853

.249

1.853

.192

.104

1.853

.249

.192
.192
.000

.104
.104
.589

1.853
1.853
22.909

.249
.249
.994

.000

.589

22.909

.994

.000

.589

22.909

.994

.000

.589

22.909

.994

186.122

1.853
1.853
22.90
9
22.90
9
22.90
9
22.90
9
2.779

.115

.148

2.779

.347

1.000

186.122

2.779

.115

.148

2.779

.347

186.122
186.122
1071.778

1.000
1.000
16

186.122
186.122
66.986

2.779
2.779

.115
.115

.148
.148

2.779
2.779

.347
.347

1071.778

66.986

517.773

16.00
0
16.00
0
16.00
0
3

172.591

5.947

.002

.271

17.842

.940

517.773

2.500

207.113

5.947

.003

.271

14.868

.904

517.773
517.773

3.000
1.000

172.591
517.773

5.947
5.947

.002
.027

.271
.271

17.842
5.947

.940
.630

1071.778

66.986
66.986
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Time * SEX

Time * Option

Time * Fitness

Error(Time)

Device * Time

Device * Time *
SEX

Device * Time *
Option

Device * Time *
Fitness

Error(Device*Ti
me)

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

154.012

3

51.337

1.769

.166

.100

5.307

.432

154.012

2.500

61.606

1.769

.176

.100

4.423

.389

154.012
154.012
196.354

3.000
1.000
3

51.337
154.012
65.451

1.769
1.769
2.255

.166
.202
.094

.100
.100
.124

5.307
1.769
6.766

.432
.240
.536

196.354

2.500

78.543

2.255

.107

.124

5.639

.483

196.354
196.354
215.626

3.000
1.000
3

65.451
196.354
71.875

2.255
2.255
2.477

.094
.153
.073

.124
.124
.134

6.766
2.255
7.430

.536
.292
.579

215.626

2.500

86.252

2.477

.085

.134

6.192

.523

215.626
215.626
1392.924

3.000
1.000
48

71.875
215.626
29.019

2.477
2.477

.073
.135

.134
.134

7.430
2.477

.579
.316

1392.924

34.824

39.883

1.571

.209

.089

4.714

.387

Lower-bound

1392.924

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

119.648

39.99
9
48.00
0
16.00
0
3

119.648

2.702

44.281

1.571

.213

.089

4.246

.365

119.648
119.648
38.366

3.000
1.000
3

39.883
119.648
12.789

1.571
1.571
.504

.209
.228
.681

.089
.089
.031

4.714
1.571
1.512

.387
.218
.145

38.366

2.702

14.199

.504

.663

.031

1.361

.139

38.366
38.366
90.539

3.000
1.000
3

12.789
38.366
30.180

.504
.504
1.189

.681
.488
.324

.031
.031
.069

1.512
.504
3.567

.145
.102
.299

90.539

2.702

33.508

1.189

.323

.069

3.213

.282

90.539
90.539
108.895

3.000
1.000
3

30.180
90.539
36.298

1.189
1.189
1.430

.324
.292
.246

.069
.069
.082

3.567
1.189
4.290

.299
.177
.355

108.895

2.702

40.302

1.430

.249

.082

3.864

.334

108.895
108.895
1218.355

3.000
1.000
48

36.298
108.895
25.382

1.430
1.430

.246
.249

.082
.082

4.290
1.430

.355
.203

1218.355

43.23
2
48.00
0
16.00
0

28.182

Lower-bound

1392.924

1218.355
1218.355

29.019
87.058

25.382
76.147

a. Computed using alpha = .05
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Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
Intercept
397.234
SEX
23.775
Option
45.735
Fitness
20.175
Error
3202.225

df

Mean Square
397.234
23.775
45.735
20.175
200.139

1
1
1
1
16

F
1.985
.119
.229
.101

Sig.
.178
.735
.639
.755

Partial Eta
Squared
.110
.007
.014
.006

Pairwise Comparisons
Measure: MEASURE_1
(I) Device
1
2

(J) Device
2
1

Mean Difference
(I-J)
.450
-.450

Sig.a
.733
.733

Std. Error
1.294
1.294

95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-2.293
3.193
-3.193
2.293

Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.

Pairwise Comparisons
Measure: MEASURE_1
(I) Time
1

2

3

4

(J) Time
2
3
4
1
3
4
1
2
4
1
2
3

Mean Difference
(I-J)
.075
-.350
-2.225
-.075
-.425
-2.300
.350
.425
-1.875
2.225
2.300
1.875

Std. Error
1.267
.923
1.444
1.267
1.200
1.284
.923
1.200
1.037
1.444
1.284
1.037

Sig.a
1.000
1.000
.857
1.000
1.000
.552
1.000
1.000
.536
.857
.552
.536

Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.
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95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-3.738
3.888
-3.128
2.428
-6.569
2.119
-3.888
3.738
-4.034
3.184
-6.161
1.561
-2.428
3.128
-3.184
4.034
-4.994
1.244
-2.119
6.569
-1.561
6.161
-1.244
4.994

Appendix M: Rating of Perceived Exertion Results
Mauchly's Test of Sphericitya
Measure: MEASURE_1
Within Subjects Effect
Device
Time
Device * Time

Mauchly's W
1.000
.716
.825

Approx. ChiSquare
.000
4.914
2.836

df

Sig.
0
5
5

.
.427
.726

Epsilonb
GreenhouseGeisser
1.000
.814
.883

Tests of Within-Subjects Effects
Measure: MEASURE_1
Source
Device

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * SEX
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * Option Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Device * Fitness Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Error(Device)
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

Time

Time * SEX

Type III
Sum of
Squares
1.680

Partial
Noncent.
Eta
Paramete Observed
Squared
r
Powera
.031
.514
.104

1

Mean
Square
1.680

F
.514

Sig.
.484

1.680

1.000

1.680

.514

.484

.031

.514

.104

1.680
1.680
4.524

1.000
1.000
1

1.680
1.680
4.524

.514
.514
1.385

.484
.484
.256

.031
.031
.080

.514
.514
1.385

.104
.104
.198

4.524

1.000

4.524

1.385

.256

.080

1.385

.198

4.524
4.524
.740

1.000
1.000
1

4.524
4.524
.740

1.385
1.385
.227

.256
.256
.640

.080
.080
.014

1.385
1.385
.227

.198
.198
.073

.740

1.000

.740

.227

.640

.014

.227

.073

.740
.740
.002

1.000
1.000
1

.740
.740
.002

.227
.227
.001

.640
.640
.982

.014
.014
.000

.227
.227
.001

.073
.073
.050

.002

1.000

.002

.001

.982

.000

.001

.050

.002
.002
52.254

1.000
1.000
16

.002
.002
3.266

.001
.001

.982
.982

.000
.000

.001
.001

.050
.050

52.254

3.266

3.174

4.811

.005

.231

14.433

.879

df

Lower-bound

52.254

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed

9.523

16.00
0
16.00
0
16.00
0
3

9.523

2.442

3.900

4.811

.009

.231

11.749

.821

9.523
9.523
5.594

3.000
1.000
3

3.174
9.523
1.865

4.811
4.811
2.826

.005
.043
.048

.231
.231
.150

14.433
4.811
8.478

.879
.540
.643

52.254

3.266
3.266
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Time * Option

Time * Fitness

Error(Time)

Device * Time

Device * Time *
SEX

Device * Time *
Option

Device * Time *
Fitness

Error(Device*Ti
me)

GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

5.594

2.442

2.291

2.826

.061

.150

6.902

.576

5.594
5.594
1.631

3.000
1.000
3

1.865
5.594
.544

2.826
2.826
.824

.048
.112
.487

.150
.150
.049

8.478
2.826
2.471

.643
.352
.215

1.631

2.442

.668

.824

.467

.049

2.012

.195

1.631
1.631
.197

3.000
1.000
3

.544
1.631
.066

.824
.824
.100

.487
.378
.960

.049
.049
.006

2.471
.824
.299

.215
.137
.067

.197

2.442

.081

.100

.936

.006

.244

.065

.197
.197
31.671

3.000
1.000
48

.066
.197
.660

.100
.100

.960
.756

.006
.006

.299
.100

.067
.060

31.671

.811

.410

.700

.557

.042

2.100

.187

Lower-bound

31.671

Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt
Lower-bound
Sphericity
Assumed
GreenhouseGeisser
Huynh-Feldt

1.230

39.07
3
48.00
0
16.00
0
3

1.230

2.648

.464

.700

.540

.042

1.854

.177

1.230
1.230
1.438

3.000
1.000
3

.410
1.230
.479

.700
.700
.819

.557
.415
.490

.042
.042
.049

2.100
.700
2.457

.187
.123
.214

1.438

2.648

.543

.819

.478

.049

2.168

.201

1.438
1.438
2.799

3.000
1.000
3

.479
1.438
.933

.819
.819
1.594

.490
.379
.203

.049
.049
.091

2.457
.819
4.781

.214
.136
.393

2.799

2.648

1.057

1.594

.209

.091

4.220

.365

2.799
2.799
2.716

3.000
1.000
3

.933
2.799
.905

1.594
1.594
1.546

.203
.225
.215

.091
.091
.088

4.781
1.594
4.639

.393
.221
.382

2.716

2.648

1.026

1.546

.220

.088

4.095

.355

2.716
2.716
28.103

3.000
1.000
48

.905
2.716
.585

1.546
1.546

.215
.232

.088
.088

4.639
1.546

.382
.216

28.103

42.37
0
48.00
0
16.00
0

.663

Lower-bound

31.671

28.103
28.103

.660
1.979

.585
1.756

a. Computed using alpha = .05
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Tests of Between-Subjects Effects
Measure: MEASURE_1
Transformed Variable: Average
Type III Sum of
Source
Squares
Intercept
508.994
SEX
1.050
Option
36.612
Fitness
79.651
Error
251.756

df

Mean Square
508.994
1.050
36.612
79.651
15.735

1
1
1
1
16

F
32.348
.067
2.327
5.062

Sig.
.000
.799
.147
.039

Partial Eta
Squared
.669
.004
.127
.240

Pairwise Comparisons
Measure: MEASURE_1
(I) Device
1
2

(J) Device
2
1

Mean Difference
(I-J)
.337
-.337

Sig.a
.255
.255

Std. Error
.286
.286

95% Confidence Interval for
Differencea
Lower Bound
Upper Bound
-.268
.943
-.943
.268

Based on estimated marginal means
a. Adjustment for multiple comparisons: Bonferroni.

Pairwise Comparisons
Measure: MEASURE_1
(I) Time
1

2

3

4

(J) Time
2
3
4
1
3
4
1
2
4
1
2
3

Mean Difference
(I-J)
-.125
-.700*
-.850*
.125
-.575*
-.725*
.700*
.575*
-.150
.850*
.725*
.150

Std. Error
.165
.172
.232
.165
.165
.184
.172
.165
.162
.232
.184
.162

Sig.b
1.000
.005
.012
1.000
.018
.007
.005
.018
1.000
.012
.007
1.000

Based on estimated marginal means
*. The mean difference is significant at the .05 level.
b. Adjustment for multiple comparisons: Bonferroni.
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95% Confidence Interval for
Differenceb
Lower Bound
Upper Bound
-.621
.371
-1.217
-.183
-1.547
-.153
-.371
.621
-1.071
-.079
-1.279
-.171
.183
1.217
.079
1.071
-.638
.338
.153
1.547
.171
1.279
-.338
.638
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